Guidance on Cancer Services

Improving Outcomes in Haematological Cancers

The Manual
Haematological cancers service guidance
Cancer service guidance supports the implementation of The NHS Cancer Plan for England,\(^1\) and the NHS Plan for Wales Improving Health in Wales.\(^2\) The service guidance programme was initiated in 1995 to follow on from the Calman and Hine Report, A Policy Framework for Commissioning Cancer Services.\(^3\) The focus of the cancer service guidance is to guide the commissioning of services and is therefore different from clinical practice guidelines. Health services in England and Wales have organisational arrangements in place for securing improvements in cancer services and those responsible for their operation should take this guidance into account when planning, commissioning and organising services for cancer patients. The recommendations in the guidance concentrate on aspects of services that are likely to have significant impact on health outcomes. Both the anticipated benefits and the resource implications of implementing the recommendations are considered. This guidance can be used to identify gaps in local provision and to check the appropriateness of existing services.

References

This guidance is written in the following context:
This guidance is a part of the Institute's inherited work programme. It was commissioned by the Department of Health before the Institute was formed in April 1999. The developers have worked with the Institute to ensure that the guidance has been subjected to validation and consultation with stakeholders. The recommendations are based on the research evidence that addresses clinical effectiveness and service delivery. While cost impact has been calculated for the main recommendations, formal cost-effectiveness studies have not been performed.

National Institute for Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA
Web: [www.nice.org.uk](http://www.nice.org.uk)

Copies of this document can be obtained from the NHS Response Line by telephoning 0870 1555 455 and quoting reference N0327. Bilingual information for the public has been published, reference N0328, and a CD with all documentation including the research evidence on which the guidance is based is also available, reference N0329.

Published by the National Institute for Clinical Excellence
October 2003

© National Institute for Clinical Excellence October 2003. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Guidance on Cancer Services

Improving Outcomes in Haematological Cancers

The Manual
## Contents

Foreword .................................................................................................................. 3  

Key recommendations.......................................................................................... 7  

Background............................................................................................................. 8  

### The topic areas

1. Access to care .................................................................................................. 26  
2. Patient-centred care ..................................................................................... 32  
3. Diagnosis and evaluation ............................................................................. 44  
4. Organisation of specialist services ............................................................. 52  
5. Treatment (excluding high dose therapy) .................................................... 68  
6. High dose therapy ....................................................................................... 84  
7. Continuing management ............................................................................. 95  
8. Palliative care .............................................................................................. 100  
9. Clinical trials and use of protocols ............................................................ 106  

### Appendices

1. Economic implications of the guidance....................................................... 109  
2. How this guidance manual was produced ................................................ 115  
3. People and organisations involved in production of the guidance ......... 117  
4. Glossary of terms ......................................................................................... 137  
5. Abbreviations ............................................................................................... 149
Foreword

Professor R A Haward,
Chairman, National Cancer Guidance Steering Group

The haematological malignancies are a complex group of neoplastic diseases, linked by their origin in bone marrow derived cells. The growing understanding of how haematological malignancies arise through disruption of the normal cellular processes in the bone marrow and immune system by a variety of molecular and cytogenetic abnormalities is challenging traditional approaches to disease classification. These advances are transforming both diagnosis and management of patients.

The characterisation of tumour cells by immunophenotypic and molecular methods is now regarded as being as important as the traditional morphological approach to diagnosis. This trend is being accelerated by the introduction of monoclonal antibody therapy and by novel drugs designed to specifically target the molecular abnormalities responsible for the development of the tumour. Such developments are of fundamental clinical importance as they increasingly define not just the diseases themselves, but how an individual patient should best be treated. Building these advances into the routine care of patients represents a demanding agenda for the clinicians and hospitals involved.

Just as the diseases are distinctive and show many differences from solid tumours, so too is the organisation of services. There is a degree of separation between the clinical services for haematological malignancies and those for solid tumours, perhaps reflecting their particular development pathways and the nature of the specialities involved. This has traditionally extended to the organisation and funding of research and many associated scientific activities.

Despite these differences, there are compelling reasons for regarding all cancer services as a logical whole, in which the diagnosis and treatment of the various disease types has an immense amount in common. Operationally the reality is that local hospital services for common solid tumours in cancer units rely in no small measure on haematology services. The active support of haematology services ‘round the clock’ underpins the safe delivery of chemotherapy for all tumour types, particularly the diagnosis and management of life-threatening complications.
Services for patients with haematological malignancies do have distinctive features. The generality of cancer patients are increasingly managed by clinicians from different professions and medical specialties, working together to combine their expertise and make collective decisions on the management of their patients. Whilst the management of haematological malignancies also involves a range of clinical and laboratory skills, the processes of diagnosis and subsequent clinical management are dominated by one medical discipline, clinical haematology. Indeed it remains perfectly possible for a patient’s diagnosis to be made by a single clinician who then goes on to initiate treatment and subsequently determines further treatment as the patient’s clinical course progresses. The same individual may also determine the point at which active therapy may no longer be appropriate for that patient. Thus for many patients, particularly those with leukaemia, it is not unusual for decisions on their management to involve only one or possibly two individual consultants, probably colleagues in the same discipline and hospital. It has been observed in some areas that less use is made of palliative services in haemato-oncology than is the case for patients with many solid tumours.

Other features of haemato-oncology services are equally characteristic. The main form of therapy for these diseases is chemotherapy (including immunotherapy). Other modalities such as radiotherapy have their roles, but these are more limited. Chemotherapy is particularly amenable to evaluation through randomised clinical trials. An admirable feature of British clinical haematology has been the widespread interest, and active participation of clinicians and hospitals, in clinical trials. Indeed, many national trials in these diseases have been extremely well supported by haematologists in all types and sizes of hospital, with high rates of trial entry. This has led to the widespread and routine adoption of evidence based protocols to help guide care in the various malignancies.

Collaboration in research has frequently been extended in other ways. In some places, but by no means all, there is professional networking between clinicians in district hospitals and between them and colleagues in more specialised units. In some places this collaboration can be very close, in others relatively token.

It is a paradox that despite the mass of trial evidence about chemotherapy regimens for the various clinical types and sub-types of disease, there is no well-established Cochrane Group and less research evidence than we would have wished to guide recommendations in some areas. Limitations in the evidence should always be acknowledged, but need not necessarily prevent important recommendations where these are consistent with other knowledge or experience in related areas. We have made some important recommendations about service organisation and delivery.
The management of individual patients should, as always, be based on sound and comprehensive diagnostic information. This is crucial in these diseases as the precise diagnosis does, in many situations, define the most appropriate treatment. Decisions on management should involve a range of knowledgeable professionals in the disease areas concerned, meeting together. They need to determine the management of individual patients as well as agreeing more general policies and operational procedures. Those managing patients with these diseases face difficult diagnostic and clinical decisions - such as defining the point at which further cycles of chemotherapy are not appropriate and change to a more palliative approach may be preferred. It is essential that this collective involvement in decision-making is adopted for haematological malignancies, as for other cancer types, even though for some disease-types most of those involved will be from one discipline. These arrangements should cover all patients and are likely to improve decisions about their care.

The number of patients with each discrete type of haematological malignancy presenting each year to cancer units is, by the standards of those who manage many solid tumours, often low. Whilst the use of protocols derived from clinical trials evidence may be a partial response to low throughput, issues remain about expertise and specialisation which cannot be easily evaded. Working collaboratively in teams, and hence being involved in decisions about the management of larger numbers of new patients than arise in any one clinician’s practice, or in a single institution, is therefore likely to be beneficial. It will facilitate the development and sharing of expertise as well as allowing a wider range of inputs into decision-making about each patient.

Thus the challenge of preparing service guidance for haematological malignancies is set against a very distinctive backcloth. Our expectation is that a more systematic team-based approach will be an important move forward. Our recommendations are designed to offer considerable flexibility in implementation, which should enable local influence over the preferred model in each place. We acknowledge that much of what is described already exists in a number of locations, and in some places these arrangements have existed for many years. However, consistency in the quality of care is our primary goal. It is evident that for some, what is being recommended represents significant but necessary change.
Key recommendations

- All patients with haematological cancer should be managed by multi-disciplinary haemato-oncology teams which serve populations of 500,000 or more.

- In order to reduce errors, every diagnosis of possible haematological malignancy should be reviewed by specialists in diagnosis of haematological malignancy. Results of tests should be integrated and interpreted by experts who work with local haemato-oncology multi-disciplinary teams (MDTs) and provide a specialised service at network level. This is most easily achieved by locating all specialist haemato-pathology diagnostic services in a single laboratory.

- There should be rapid-access diagnostic services for patients with lymphadenopathy (chronically swollen lymph nodes or neck lumps).

- Clinical nurse and palliative care specialists are to have central roles in haemato-oncology teams, working closely with their medical colleagues. Clinical nurse specialists will arrange for patients and carers to receive multi-faceted support, coordinated care, and all the information they want, throughout the course of the illness.

- MDTs which manage patients with acute leukaemia should provide treatment intended to induce remission for sufficient new patients for the units concerned to develop and maintain expertise. Services are unlikely to be viable with five or fewer new patients per year. This treatment should be provided at a single facility within any one hospital site, in designated wards with continuous access to specialist nurses and haematologists.

- High dose therapy with progenitor cell transplantation is to be carried out only in centres which meet JACIE accreditation standards, including the minimum case-load criterion of 10 procedures per annum.
Background

Scope of this document

The purpose of this guidance is to describe key aspects of the service required to achieve the best outcomes for adult patients with haematological cancers. The guidance covers all aspects of care for this group of patients, including medical diagnosis and management.

Guidance on paediatric and adolescent services is expected from the newly-established National Institute for Clinical Excellence (NICE) Collaborating Centre for Cancer. It will be for that guidance to propose the definition of the interface between their service scope and the work of adult services covered by this guidance.

This background section is intended to help non-expert users of the manual to orientate themselves to this group of diseases and their management.

Haematological cancers: nature and numbers

Haematological cancers (cancer of blood cells) together represent the fifth most common type of cancer in the UK, accounting for 7% of all cancers. This is a uniquely diverse group which is sub-divided into three main diseases: leukaemia, lymphoma and myeloma. Some forms are highly aggressive, others so benign that they may only be picked up by chance; the symptoms can include lumps (in a variety of body sites), which are typical of lymphomas; bone fractures and kidney problems, characteristic of myeloma; and fatigue and vulnerability to infection, which can result from most types of haematological cancer but are particularly severe in acute leukaemia.

Like the forms of disease, the treatments used vary widely. Some are very demanding, both for patients and those who look after them. Aggressive forms of haematological cancer such as acute leukaemia may be curable, but only by repeated periods of intensive chemotherapy which requires long periods of hospitalisation and protection from infection, and sometimes, transplantation of blood progenitor cells from bone marrow or other sources. A wider range of treatments is needed for patients with lymphomas or myeloma,
including chemotherapy, radiotherapy and sometimes surgery; with lymphomas as with acute leukaemias, intensive treatment may continue over long periods of time. Less aggressive forms of haematological cancer, which are more common among elderly people, may only require monitoring or minimal palliative treatment, often given on an out-patient basis.

Despite these variations, the underlying problem is basically the same in all these diseases: a genetic change in a particular group (clone) of blood cells (or its precursor) that leads these cells to develop incorrectly and multiply in a disorganised and uncontrolled manner, crowding out cells that are essential to normal function. The diversity in the form of disease produced results from a combination of factors, particularly the type of cell affected, the nature of the genetic change that precipitates the malignancy, and the point in the cell’s maturation process at which the malignant change occurs.

Blood cells begin their development in the bone marrow. When genetic disruption occurs at this point, cancer replaces the cells which would normally develop into oxygen-carrying red blood cells, platelets which are essential for clotting, and white cells that fight infection. This produces leukaemia, a disease characterised by anaemia, fatigue, bleeding, and susceptibility to infection.

As they mature, white blood cells (lymphocytes) migrate from the bone marrow and settle in lymph nodes or other parts of the immune system – in particular, the lining of the intestine, the skin, or the lungs – where their development continues. Malignant changes at this point in the cell’s life cycle produce lymphomas. These tend to reveal themselves as lumps but they also produce a variety of other symptoms.

One particular type of blood cell (plasma cell) returns to the bone marrow for the final period of its life. When malignant changes occur here, excessive numbers of abnormal plasma cells destroy the surrounding bone. This is myeloma, usually known as multiple myeloma because it tends to happen in many parts of the skeleton simultaneously.
Prevalence, incidence and survival rates

There are no precise and reliable figures for incidence and survival rates for the different forms of haematological cancer in England and Wales. Whilst the Office for National Statistics (ONS) and the Wales Cancer Intelligence and Surveillance Unit do publish descriptive statistics (Table 1), there are many problems with these figures. For example, there is evidence that many cases are never reported to cancer registries, so the actual number of patients could be substantially higher than national figures suggest.¹

With some of these diseases, it can be difficult to decide which individuals should be defined as patients. Blood changes which could be classified as chronic leukaemias are widespread among older people and often produce no symptoms. Incidence rates for these conditions therefore depend largely on whether anyone happens to look at blood samples from such individuals, and on clinicians’ criteria for deciding whether malignancy exists at all. Even when it is clear that haematological malignancy is present, identifying the particular form of cancer requires sophisticated methods which are not available in many local hospitals, so a large number of registrations do not include detailed information on the diagnosis. This is especially true of non-Hodgkin’s lymphoma (NHL), a large and varied group of conditions; indeed, the largest group of NHL registrations in ONS statistics is described as “unspecified”. This issue is discussed in more detail below.

¹ The establishment of a new reporting system in the South Thames East Area was associated with an increase of 43% in annual registrations. (South Thames Haematology Specialist Committee and Thames Cancer Registry. Report of the South Thames Haematology Register Cancer Sub-Committee on the Incidence of Haematological Malignancies in 1999. London: King’s College, 2001.) This is consistent with anecdotal evidence suggesting that many cases are not reported.
Table 1. Haematological malignancies: incidence, survival rates and deaths, England and Wales (ONS figures)²

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Disease Codes</th>
<th>Incidence: crude rate per 100,000 1999</th>
<th>Deaths 2000</th>
<th>Death rate per 100,000 2000</th>
<th>Relative survival</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ICD 9</td>
<td>ICD 10</td>
<td>No of cases</td>
<td>One year</td>
<td>Five year</td>
</tr>
<tr>
<td>Acute lymphoblastic leukaemia (ALL)</td>
<td>204.0</td>
<td>C91.0</td>
<td>593</td>
<td>1.1</td>
<td>252</td>
</tr>
<tr>
<td>Acute myeloid leukaemia (AML)</td>
<td>205.0</td>
<td>C92.0</td>
<td>1779</td>
<td>3.4</td>
<td>1604</td>
</tr>
<tr>
<td>Chronic myeloid leukaemia (CML)</td>
<td>205.1</td>
<td>C92.1</td>
<td>605</td>
<td>1.1</td>
<td>508</td>
</tr>
<tr>
<td>Other &amp; unspecified leukaemias</td>
<td>204.2-204.9</td>
<td>C91.2, C91.3, C91.5-91.9, C92.3-C95</td>
<td>751</td>
<td>1.4</td>
<td>392</td>
</tr>
<tr>
<td>Chronic myeloproliferative disorders (MPD)</td>
<td>238.1</td>
<td>D47.1</td>
<td>643</td>
<td>1.2</td>
<td>173</td>
</tr>
<tr>
<td>Myelodysplastic syndrome (MDS)</td>
<td>284.9, 285.0</td>
<td>D46</td>
<td>2047</td>
<td>3.9</td>
<td>110</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>203</td>
<td>C90</td>
<td>2991</td>
<td>5.7</td>
<td>2024</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma</td>
<td>201</td>
<td>C81</td>
<td>1218</td>
<td>2.3</td>
<td>241</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma (NHL)</td>
<td>200, 202</td>
<td>C82-85, C91.4, C96</td>
<td>8075</td>
<td>15.3</td>
<td>4012</td>
</tr>
<tr>
<td>Chronic lymphocytic leukaemia (CLL)</td>
<td>204.1</td>
<td>C91.1</td>
<td>2071</td>
<td>3.9</td>
<td>778</td>
</tr>
</tbody>
</table>

a The level of underreporting, particularly of non-malignant cancers (ICD10 D codes), is not known.


² Data provided by the National Cancer Intelligence Centre, Office for National Statistics, on request, October 2002.
Despite the problems with statistics, basic information is essential to plan service provision. Registration figures suggest that 39 new cases per 100,000 population are reported per annum, but those working in the field believe that the numbers are considerably higher. It is also crucial for service planning to know how many patients are likely to require intensive or complex forms of treatment, so varied groups of conditions like NHL must be split into aggressive, or ‘high grade’ and less aggressive ‘low grade’ forms, sometimes described as indolent lymphomas. Table 2 attempts to do this, although the figures are acknowledged to be estimates, particularly since the distinctions between some of these groups (such as high-grade and low-grade lymphoma) are often unclear.

Table 2. Haematological cancers: estimated annual incidence

<table>
<thead>
<tr>
<th>Disease</th>
<th>Incidence, England and Wales</th>
<th>Per million population</th>
<th>Per 500,000</th>
<th>Per 250,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute leukaemia</td>
<td>2400</td>
<td>48</td>
<td>24</td>
<td>12</td>
</tr>
<tr>
<td>CML</td>
<td>500</td>
<td>10</td>
<td>5</td>
<td>2-3</td>
</tr>
<tr>
<td>CLL</td>
<td>4000</td>
<td>80</td>
<td>40</td>
<td>20</td>
</tr>
<tr>
<td>NHL ‘high grade’</td>
<td>2000</td>
<td>40</td>
<td>20</td>
<td>10</td>
</tr>
<tr>
<td>NHL ‘low grade’</td>
<td>5000</td>
<td>100</td>
<td>50</td>
<td>25</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma</td>
<td>1200</td>
<td>24</td>
<td>12</td>
<td>6</td>
</tr>
<tr>
<td>Myeloma</td>
<td>3000</td>
<td>60</td>
<td>30</td>
<td>15</td>
</tr>
<tr>
<td>MDS/MPD/other</td>
<td>2000</td>
<td>40</td>
<td>20</td>
<td>10</td>
</tr>
</tbody>
</table>

Incidence and mortality rates vary across England, with relatively high rates in the South West – around 50% higher than in Yorkshire. The reasons for these geographical variations are not known, but are likely to include variations in diagnosis and reporting.

The overall prevalence of haematological cancer is rising, with the greatest increase in the number of people with non-Hodgkin’s lymphoma. The rate of diagnosis has increased by 3-5% per annum between 1984 and 1993; ONS figures show that the age-standardised

---

3 Estimated figures based on expert opinion from the editorial board.

incidence rose almost three-fold between 1971 and 1997. The increased rate of diagnosis almost certainly reflects a real increase in incidence.\textsuperscript{5}

Prevalence is also increased by improved survival rates. Before the 1970s, non-Hodgkin’s lymphoma was usually fatal, but developments in therapy between 1971 and 1986 led to a 14\% increase in five-year survival rates. Similar improvements are apparent for leukaemia: five-year survival rates have doubled since the early 1970s. In multiple myeloma, substantial improvements have been achieved in short-term (one- to three-year) survival rates, although longer term survival rates remain poor.\textsuperscript{5}

Incidence and survival rates vary greatly with age. In people under the age of 60, five-year relative survival rates for leukaemia are around 40\%; but in those over 70, only 20-25\% survive this long after diagnosis. Age-related differences in survival time are particularly marked in acute myeloid leukaemia (AML). Leukaemia incidence and mortality rates have risen sharply in the elderly but not so much in younger people, which tends to depress overall survival rates. Similar patterns can be seen for other forms of haematological cancer, although aggressive lymphoma in older patients is unlike acute leukaemia in that it can often be successfully treated.

Considered as a group, haematological cancers become more common as populations age. The number of new cases among adults almost doubles with each decade between 20 and 60, and continues to rise until the eighth decade (Figure 1).

\textbf{Figure 1. Number of new cases of haematological cancers (all types, combined) by age group, 1997}\textsuperscript{5}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Figure1}
\caption{Number of new cases of haematological cancers (all types, combined) by age group, 1997}\textsuperscript{5}
\end{figure}

It is not possible to judge whether outcomes for patients in Britain are better or worse than elsewhere. Survival rates in England and Wales are reported to be below the European average and lower than in the USA, but these apparent differences may not accurately reflect reality. For example, mortality statistics for haematological cancers are particularly unreliable because many patients die from infections and these, rather than the underlying cancer, may be recorded as the cause of death; and when national descriptive statistics are unreliable, international comparisons will be even more misleading.

**Classification**

One of the reasons for the lack of trustworthy statistics is that a reliable classification system for haematological malignancies has only recently been developed and agreed by oncologists and pathologists. Accurate classification is important because each type of haematological cancer has unique characteristics. To assess prognosis and select the optimum form of therapy, it is essential to know precisely what type of cancer the patient has.

There have been numerous attempts at classification, with 25 different systems recorded for lymphoma alone over the last quarter-century. The classification problem has recently been resolved by the development of the REAL/WHO system, which has been adopted by most pathologists in the UK. This allows the diagnosis of leukaemias and lymphomas to be cross-checked and agreed by laboratory-based pathologists and clinicians. Regrettably, the REAL/WHO system can be difficult to relate to classification systems on which national population statistics are based.

The REAL/WHO classification system is based on a combination of features, which together define the type of cancer. These are:

- Morphology of the tumour cells - their shape, size and general appearance under a microscope;
- Immunophenotype - specific proteins produced by tumour cells;
- Genetic features - mutations or abnormal arrangements of genes;
- Clinical features, including symptoms.

Although the REAL/WHO system was developed for lymphomas, the precise diagnosis of leukaemia is based on similar criteria. An initial diagnosis of acute leukaemia may be made on the basis of the patient’s symptoms and the microscopic appearance of a blood sample, but, as with lymphoma, discrimination between sub-types and treatment selection requires a wider range of diagnostic tests.
Symptoms and treatment

Leukaemias
Leukaemias tend to produce generalised symptoms, notably fatigue, bruising, bleeding and reduced resistance to infection. The severity of disease, rate of progression and treatment varies greatly between leukaemias, so precise identification of the specific form of leukaemia is crucial to optimum management.

Acute leukaemia
This is a group of rapidly-progressing diseases, which includes acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL). Acute leukaemia can affect adults of any age, but the incidence of AML rises sharply in middle age and is highest among elderly patients, whilst most people with ALL are under 65.6 These diseases cause severe anaemia which makes sufferers feel absolutely exhausted; they are prone to repeated infections because they cannot produce enough normal blood cells to mount an effective immune response.

Acute leukaemia is treated with intensive chemotherapy, given on an in-patient basis through intravenous catheters, over periods of about four weeks at a time. Patients undergoing such treatment are extremely vulnerable to life-threatening infections (neutropenic sepsis) and great care has to be taken, both to minimise the risk of infection and to treat it rapidly and effectively when it occurs. Specialist nursing and 24-hour cover by appropriately trained medical staff are required.

Stem cell rescue – infusion of tissue from which blood cells develop – may be used in the hope of re-populating bone marrow destroyed by chemotherapy with healthy cells. This may require a transplant of donated bone marrow that closely matches the patient’s own (allogeneic bone marrow transplant, or BMT) or re-infusion of cells taken from the patient before high dose chemotherapy (autologous stem cell rescue). Both methods carry specific risks: graft-versus-host disease with allogeneic transplants, or re-seeding with tumour with autologous transplantation.

Although acute leukaemia is sometimes cured, it frequently goes into remission after treatment, only to recur some time later. When this happens, the treatment may be repeated, perhaps intensified. It can be very difficult to judge the point at which attempting to cure leukaemia ceases to be in the best interest of the patient.

Chronic leukaemia
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia, but it may also be classified as a form of lymphoma. It is most often found in elderly people. The effects of CLL vary widely; some people feel quite well and the condition is discovered incidentally; others may experience gradually increasing fatigue, repeated infections, sweats, bleeding problems, swollen lymph nodes and a swollen spleen which can become painful. A wide range of treatments may be used and there is considerable uncertainty about optimum management.

The second major form of chronic leukaemia is chronic myeloid leukaemia (CML). Younger people with CML can achieve long-term freedom from the disease after high dose therapy and transplantation of bone marrow from a matched donor (allogeneic BMT); although risky, this is currently the only curative treatment. Palliative measures may keep the symptoms under control for a few years, but the progress of the disease cannot be halted except by BMT; without this, CML is invariably fatal. Imatinib (Glivec) is a new form of treatment for CML, the first of a range of drugs designed to target the specific abnormal proteins produced by the cancer. This approach seems very promising but its long-term effects are unknown.7

Myeloproliferative disorders (MPD)
These are chronic conditions caused by bone marrow abnormalities, which usually affect older patients. People with myeloproliferative disorders may experience few problems at first, but fatigue is common as the condition progresses. Some develop night sweats, enlarged and painful spleens, bleeding or circulation problems, thromboses and other symptoms, depending on the condition. Out-patient supportive treatment or single agent therapy is normally sufficient, but some patients develop vascular complications and require treatment from other clinical specialists.

Myelodysplastic syndrome (MDS)
Like myeloproliferative disorders, myelodysplastic syndrome is caused by abnormal bone marrow and tends to affect older patients. It causes progressive marrow failure, leading to anaemia, problems with blood clotting and reduced resistance to infection. People with these diseases are usually given supportive care and regular transfusions on an out-patient basis. In about 30% of cases, myelodysplastic syndrome turns into acute myeloid leukaemia; when this occurs in younger patients, bone marrow transplantation may be offered.

Lymphomas

Lymphoma, the most common type of haematological cancer, includes a wide range of conditions. Lymphomas tend to produce lumps in lymph nodes; some forms affect other tissues such as the skin, lung or gut. Traditionally, lymphomas have been divided into Hodgkin’s disease (now known as Hodgkin’s lymphoma) and non-Hodgkin’s lymphoma (NHL), but NHL is a diverse group of conditions which is often sub-divided into aggressive and indolent forms. This distinction is, however, blurred, because some normally indolent diseases are capable of progressing quite rapidly.

Hodgkin’s lymphoma

Hodgkin’s lymphoma is most common in relatively young people, with maximum incidence rates between the ages of 20 and 30, although it can affect adults of any age. It usually produces a painless lump in the neck, but lumps can develop in other parts of the body such as the chest. Other symptoms include recurring fevers and night sweats, weight loss and itchy skin.

It is often possible to cure Hodgkin’s lymphoma with appropriate treatment. Decision-making about treatment depends on accurate staging, which requires specialist cross-sectional imaging facilities. Hodgkin’s lymphoma is usually treated with multi-agent chemotherapy, given on an out-patient basis for several months. Radiotherapy may be given for localised or bulky disease or to treat masses that persist after chemotherapy. High dose chemotherapy with stem cell rescue can be offered to patients whose disease fails to respond to initial treatment, or who relapse after treatment.

Many patients with Hodgkin’s lymphoma will want to have children after treatment. They are particularly likely to need fertility services.


People with aggressive non-Hodgkin’s lymphomas usually develop lumps, which may grow quite rapidly. Although these lumps most often form in the neck, they can occur in other body sites, including the groin, abdomen, or armpit; on the skin, in the brain, lung, or bone marrow. By the time the condition is diagnosed, most patients have widespread disease, with fever, fatigue, weight loss and night sweats.

The most common aggressive lymphoma is DLBCL, which accounts for about 30% of new cases of NHL. AIDS-related lymphoma is a particularly aggressive condition. Burkitt’s lymphoma produces fast-growing tumours in the abdomen.
Precise identification of the form of lymphoma and accurate staging using cross-sectional imaging is crucial both for choosing the optimum form of treatment and for monitoring progress. This requires specialist diagnostic staff and facilities. Most patients are treated on an outpatient basis with multi-agent chemotherapy over several months, but those who have very aggressive conditions such as Burkitt’s lymphoma require in-patient treatment. Radiotherapy may be used to reduce bulky or localised tumours. About half of the total number of patients with aggressive lymphomas will need second-line therapy, sometimes high dose chemotherapy. Several trials are investigating the role of monoclonal antibodies in the treatment of lymphoma.

**Less aggressive (“low-grade” or “indolent”) lymphomas**

Indolent, or low-grade, are misleading terms which should not be taken to mean minor: these diseases are usually incurable and eventually fatal. However, their rate of progression may be slow, with median survival periods of up to 10 years for some follicular lymphomas.¹ Like chronic lymphocytic leukaemia (CLL), which can be classified as a member of this group, these conditions tend to affect older people. Follicular lymphoma, which accounts for 22% of all cases of haematological cancer, is the most common form. Others include Waldenstrom’s lymphoma and marginal zone lymphomas. Some types of marginal zone lymphoma form in lymph nodes, whilst others produce tumours outside lymph nodes – for example, on the skin or in the stomach lining.

The clinical presentation, rate of disease progression and patterns of treatment vary widely. The disease may continue for a decade or more and treatment is not always required; watchful waiting, with appropriate interventions when symptoms develop, is often the best option.

In a small minority of cases, the disease is localised and may be curable, for example by radiotherapy to a single lymph node. Usually (in probably 85-90% of cases), the disease has spread by the time of diagnosis and these patients are not likely to be cured. Nevertheless, there is much that can be done.

Selecting the most appropriate form of intervention is a complex decision process that must be re-visited each time the patient relapses. Once treatment becomes necessary, it is likely to be needed for the rest of the patient’s life. Most patients are treated with single agent chemotherapy on an out-patient basis, but some will require regular supportive treatment such as blood transfusions and plasma exchange to manage blood abnormalities. There may be multiple episodes of remission and relapse, and the nature of the disease can change at relapse – often to a more aggressive form.

---

Patients with extra-nodal forms of NHL – that is, lymphomas that develop outside lymph nodes, such as those which affect the skin or intestine – may currently be treated by specialists who deal with that particular body system, particularly dermatologists and gastroenterologists. However, since these are systemic diseases, local treatment is rarely sufficient.

Younger patients who relapse after initial treatment may be offered high dose therapy, and there are several trials in progress to establish whether the benefits of such aggressive treatment justify the difficulties and risks. There are also several on-going trials of monoclonal antibodies such as rituximab. This approach to treatment is expected to become increasingly important in the future.

**Myeloma and monoclonal gammopathy of uncertain significance (MGUS)**

Myeloma causes painful, crippling bone destruction. As the disease progresses, the bones become very fragile and prone to fracture. Most patients present with persistent bone pain (usually backache), general malaise, and symptoms caused by blood abnormalities such as headaches and bleeding. Destruction of the bones produces high levels of calcium in the blood, which causes tiredness, thirst, nausea, and kidney problems. Some patients develop neurological problems such as spinal cord compression.

Many of these patients may be referred initially to hospital departments other than haematology – in particular, rheumatology, orthopaedics, and renal medicine. This may result in considerable delay in diagnosis. Myeloma is diagnosed by blood tests, examination of bone marrow, and imaging.

Myeloma is not curable but chemotherapy can often induce temporary remission. Typically, patients experience repeated periods of relapse, treatment and remission over the course of some years until the disease can no longer be controlled. High dose therapy with stem cell rescue is being increasingly used for those who can tolerate it, to reduce symptoms and increase survival time.

Patients with myeloma require treatment by a range of specialists, including haematologists, neurologists, oncologists, orthopaedic surgeons, pain specialists and renal specialists.

MGUS – monoclonal gammopathy of uncertain significance – is an abnormality which may be found on blood tests. Of itself, it produces no symptoms, but it can turn into myeloma or other haematological malignancies. In many people, MGUS remains stable and no active treatment is required.
Long-term impact of treatment for haematological cancer

Curative treatments for haematological cancer, particularly intensive or high dose therapies, can have lasting effects. These include a markedly increased risk of secondary primary cancers, particularly among people treated for Hodgkin’s lymphoma. Secondary leukaemias have been linked with chemotherapy, and solid tumours, such as breast and lung cancers, with radiotherapy used to treat leukaemia or lymphoma. All these forms of cancer tend to emerge at a younger age in long-term survivors of haematological cancer than in the general population.9

Long-term hormone-related problems are also relatively common. Most patients will be rendered infertile by treatment for haematological cancer, and fertility services are important to enable at least some younger patients to have children.

Epidemiology, causes and trends

As stated earlier, the incidence of haematological malignancy, particularly NHL, appears to be rising quite rapidly. If this rate of increase continues, NHL will become one of the most common cancers in the next few years.10 Although some of this apparent increase could be due to better case-finding, it is likely that there has been a real rise in the incidence of haematological cancers. Environmental pollution – both chemical pollution and radiation – is believed by many to be the underlying cause of a substantial part of the rise in these forms of cancer, but there is not yet sufficient reliable evidence to draw firm conclusions on this.11

Immune system depression, which has been linked with many forms of haematological cancer, affects increasing numbers of people. This can be due to diseases such as HIV, to drugs used to prevent rejection of transplanted organs, or to cytotoxic treatment (chemotherapy or radiotherapy), especially prolonged treatment with alkylating agents such as cyclophosphamide. All are becoming more common.

9 This information is derived from studies summarised in Improving Outcomes in Haematological Cancers, The Research Evidence. Available on the NICE website: <www.nice.org.uk>


Immunosuppression can also be caused by agricultural and industrial chemicals, and such chemicals could be responsible for at least some of the rise in incidence of NHL. There are local excesses of NHL in rural areas, relatively high incidence rates among farmers and horticulturalists, and associations between exposure to agricultural biocides and risk of NHL. However, whilst atrazine, lindane and phenoxy herbicides such as 2,4-D have all been implicated in some studies, current evidence does not show a clear-cut association between any specific agricultural chemical and lymphoma.  

Petrochemicals have been linked with various forms of haematological cancer. Benzene is particularly hazardous; long-term exposure is known to damage the bone marrow and to cause myeloid leukaemia. These effects are dose-related but sensitivity varies widely between individuals. Benzene is widespread in the environment – it is found, for example, in cigarette smoke, engine exhaust and petrol fumes – but it is not known whether low concentrations precipitate leukaemia. The risk of acute myeloid leukaemia is doubled in people who smoke 20 cigarettes daily; about half of this excess risk can be attributed to the benzene content of cigarette smoke.

Exhaust from petrol and diesel engines contains several harmful chemicals. Exposure to engine exhaust significantly increases the risk of multiple myeloma, but recent analyses suggest that benzene is not the causative agent, which remains unknown.

Associations have also been found between exposure to tetrachloroethylene, a solvent widely used for dry cleaning and degreasing, and various forms of cancer including NHL. Although the published evidence for increased risk of NHL among people working with tetrachloroethylene is limited to three cohort studies, their results are consistent. Tetrachloroethylene is known to cause leukaemia in rats.

16 International Association for Research into Cancer (IARC) monograph vol. 63 on tetrachloroethylene, available on <http://monographs.iarc.fr>
NHS services for haematological cancers

A range of different levels of service, corresponding with the variety of forms of disease, is required to manage patients with haematological cancers. Patients with acute leukaemia may need repeated periods of intensive in-patient treatment lasting over three or four months; most will be re-admitted many times over a period of years. Hospital episode statistics show that haematological cancers account for about 17,000 in-patient bed days per million population per year, but the actual figure could be substantially higher than this. By contrast, patients with conditions at the opposite end of the spectrum of aggressiveness may need little more than regular monitoring.

The range of degrees of complexity of hospital treatment may be summarised as follows; the levels correspond with those specified by the British Committee for Standardisation in Haematology (BCSH).\(^\text{17}\)

**Level 1** Hospitals providing conventional chemotherapy and other forms of out-patient treatment, using dose levels that would not be expected to produce prolonged neutropenia.

This level may be subdivided into five types of service:

i. Out-patient assessment and monitoring.

ii. Out-patient chemotherapy and haematological support (e.g. oral chemotherapy for CLL and palliative interventions for myeloproliferative disorders).

iii. Day case chemotherapy e.g. for NHL.

iv. In-patient chemotherapy and palliative treatment, e.g. for patients with NHL who cannot cope with day case treatment.

v. Facilities for management of neutropenic sepsis.

**Level 2** Facilities for remission induction in patients with acute leukaemia, using intensive chemotherapy regimes. This level of facility is also required to treat patients with aggressive lymphoma.

**Level 3** Facilities for autologous transplantation, using the patient’s own bone marrow or peripheral blood stem cells.

\(^{17}\) The four levels of care defined by BCSH are described in *Guidelines on the provision of facilities for the care of adult patients with haematological malignancies*, available on the BCSH website at: <www.bcsghguidelines.com/pdf/CLH3.pdf>
Level 4 Centres with expertise in both autologous and allogeneic transplantation, which provide bone marrow transplants from matched donors.

It is believed that over a hundred hospitals in England and Wales provide treatment at Levels 1 to 2; another 50 carry out autologous transplantation (Level 3), of which about 30 also carry out allogeneic transplants (Level 4). Accreditation standards for bone marrow transplantation (available on www.ebmt.org) specify that any hospital which offers stem cell rescue - whether autografts or allografts - should carry out a minimum of 10 procedures of the type offered per year. Returns to the European Group for Blood and Marrow Transplantation (EBMT) suggest that this criterion is not met in all Trusts.18

Complex chemotherapy for induction of remission in acute leukaemia (Level 2) is just as clinically complex, demanding and risky as autografting, with treatment-related death-rates of up to 25% in patients over 60 years old and around 8% in younger patients. This emphasises the importance of all units performing this work having sufficient experience, staff, and facilities to deliver these treatments safely and effectively.

At present, patients with leukaemias and most other forms of haematological cancer are managed by haematologists. Although Trusts vary widely, NHS services for patients with leukaemia have some impressive features. The proportion of patients entered into clinical trials is high; haematologists are particularly likely to work to protocols; and follow-up systems are often good. There is a high level of networking between haematologists, which may be seen as a rational way of coping with individual lack of specialisation in haematological malignancy. Pooling knowledge by involvement in trials, extensive use of protocols and consultation with colleagues tends to improve the probability that individual patients are offered the most effective treatment.

Problems are more likely to occur with types of haematological cancer other than acute leukaemia, where the cause of the symptoms may be more difficult to identify. The symptom patterns within the spectrum of haematological malignancy are very variable, so patients who are not referred directly to a haematologist may take a range of routes through the system, seeing a series of specialists before a diagnosis is established.

Current services are, moreover, very heterogeneous. Although some parts of England have established formal multi-disciplinary team (MDT) working, with specified teams for each major form of haematological cancer; many haematologists in other areas are accustomed to working without such support; some, indeed, work effectively single-handed. The level of integration between oncology and haematology also varies widely and it may not be clear where responsibility for some patients should lie.

Some specific aspects of NHS services give particular cause for concern. For example, there is evidence showing an unacceptably high rate of errors in diagnosis (see Topic 3, Diagnosis and evaluation). Current diagnostic services fall into four broad categories:

1. Fully integrated specialist diagnostic laboratories.

2. Services spread over different laboratories. Typically, pathology, haematology and immunology departments share the workload. With this way of working, the results have to be integrated into a single interpretative report containing all the information relevant to the management of the patient, to avoid duplication and possible contradictions that may arise when key investigations are carried out in separate laboratories.

3. Access to some specialist technical services. Many district general hospital laboratories can carry out a limited range of diagnostic tests on site, with reports on tissue specimens (e.g. lymph node biopsies) provided by general pathologists whilst blood and bone marrow specimens are assessed by the haematologist who also treats the patients. Some specimens may be referred to larger centres for specialist investigations.

4. No access to specialist diagnostic services (this is not believed to be a common situation).

Even when specialist diagnostic review is available, treatment plans are not always altered when expert review suggests that an alternative treatment would be more appropriate. This suggests poor integration between diagnostic and clinical services.

The level of expertise of clinical staff also varies widely from Trust to Trust. Patients report excellent services in some hospitals, but obvious inadequacies - lack of suitably trained nurses, for example - in others. An adequate service requires high levels of staffing by nurses and doctors who have sufficient expertise to respond appropriately to medical crises which may occur at any time without warning. A single-handed haematologist simply cannot provide this level of care all the time.
Lack of integration between haematology and other clinical disciplines means that people with haematological malignancies may not have access to services from which they would benefit. Haematologists who treat these patients need to be able to work closely with other disciplines, particularly oncology (including adolescent oncology), palliative care services and services for the elderly. Such integration would benefit patients and reduce the load on haematologists.

**Commissioning services for haemato-oncology**

All bodies which commission services for patients with haematological cancers within each cancer network should work together to ensure that these services function in a co-ordinated way. Smaller networks may collaborate and pool resources to deliver a full range of services. These issues are further discussed in Topic 4, *Organisation of specialist services.*
This version of the guideline includes the 2003 recommendations and any amendments made to these as part of the 2016 update. See the addendum and short version of the guideline for the full list of 2016 recommendations.

Recommendations updated in 2016 are marked as:

- [new 2016] if the evidence has been reviewed and the recommendation has been added or updated
- [2016] if the evidence has been reviewed but no change has been made to the recommended action.
- [2003, amended 2016] if the evidence has not been reviewed but changes have been made to the recommendation wording that change the meaning (details of these changes can be found in the Update information section of the short version of the guideline)

1. Access to care

This chapter has been updated and replaced by the NICE guideline on suspected cancer.
2. Patient-centred care

It is anticipated that the National Institute for Clinical Excellence (NICE) guidance on improving supportive and palliative care for adults with cancer will be published in 2003. This guidance is intended to complement this manual, giving detailed and specific recommendations on many of the issues introduced in this section as they apply to cancer care generally, with supporting evidence. It will cover the following topic areas:

- Co-ordination of care;
- Face-to-face communication;
- Information;
- Psychological support services;
- Specialist palliative care services;
- General palliative care services;
- Social support services;
- Rehabilitation services;
- Complementary therapy services;
- Spiritual support services;
- Carer and bereavement support services;
A. Recommendations

Clinical nurse specialists

Clinical nurse specialists should be available to provide support for patients with haematological cancer. These nurses should have specific training in communication, counselling and ethics; they should be full members of haematological cancer multi-disciplinary teams, with specific responsibility for facilitating the provision of patient-centred care and the involvement, as necessary, of other professionals. They will provide information and support for patients and help other clinical staff to acknowledge and give full consideration to individual patients’ perspectives. (See Topic 4, Organisation of specialist services.)

From the time of diagnosis, each patient should have access to a specific clinical nurse specialist who can offer psychosocial support and continuity of care. Each patient and his/her carer should be given a telephone number so that they can contact this nurse when they feel they need information, help or support. Whilst most people with cancer are primarily concerned that their chances of survival should be maximised through appropriate treatment, it is important that their other needs are also recognised and met. These include emotional and practical needs, and may range from simple human contact and reassurance to help and advice on practical issues such as getting appropriate and acceptable food in hospital.

The counselling role of the clinical nurse specialist is likely to be particularly important in haematological cancer. For some patients, the balance between the potential survival benefits of treatment and the risk and suffering that the process may
entail is such that the decision about whether to go through with it is very difficult. For others, such as older patients with acute leukaemia, and those for whom repeated efforts to control the disease have failed, the risks of intensive treatment may make it inadvisable. In these cases, in particular, counselling by a clinical nurse specialist who understands both the nature of the disease and the dilemma faced by the patient, and with whom patients and carers feel they can talk freely, can be especially valuable.

Information for patients

A recurring theme in patients’ experiences of services for haematological cancer is lack of information: first about their diagnosis, and later about what may happen to them. Effective systems should be established to ensure that clear, honest and consistent information is given to patients from the outset.

Clinical nurse specialists can play crucial roles in ensuring that patients and carers understand both what is happening to them and what is likely to happen as they progress through the various phases of their illness and treatment, but all those involved in caring for these patients should adopt an attitude of openness and willingness to share information.

The consultation at which patients learn that they have cancer is a crucial event. Sensitive and compassionate communication is essential. This is, literally, a life-changing experience for patients.1 Although factual details may be forgotten, the way the news that they have cancer is broken is often remembered with great clarity; it colours later relationships with health professionals, establishing either trust or deep resentment. In haematological cancer, there is

---

often more than one “bad news” consultation during the course of the disease.

Patients should be encouraged to bring a close friend or relative to “bad news” consultations. The consultation should be held in a private room by a senior clinician, preferably the individual who will be responsible for the patient’s future care. Adequate time should be allowed for explanation and there should be no interruptions.

The nurse specialist should be present during this consultation and should remain with the patient afterwards to offer support and further information tailored to individual needs. Other people, such as students, should only be present with the patient’s explicit consent.

All clinicians, particularly those in senior positions, should have specific training in communication skills. Such training should also be available for other health professionals who have responsibility for face-to-face care.

When there is a choice between different therapeutic approaches, patients should be offered the opportunity to discuss the options in a joint meeting with the clinicians who would be responsible for their treatment and the specialist nurse. Providers should ask patients if they want additional information and seek to discover how much they wish to be involved in discussions about treatment. If there is uncertainty about what treatment might be necessary, patients should be given realistic information about the different possibilities. Clinicians should tell patients as early as possible if they have reason to believe that successive courses of treatment will be required, that recovery could entail an extended period of time, or that the disease is incurable.

It is important that patients’ views about treatment are respected. Different individuals vary widely in their attitudes
and in their willingness to tolerate cancer treatment, and their views may change from time to time. Some would choose the chance of extended survival at almost any cost, some would rather die of their disease than undergo intensive therapy, and others may choose to defer radical treatment until after what they regard as a crucial life priority such as having a baby.

Patients should be offered as much information about their disease and its treatment as they wish to have, in forms they can use and language they are likely to understand, and at a rate they can assimilate. Doctors should ask patients what they want to know and about their concerns, and check that they understand what they have been told. Patients often find it difficult to take in information given during the consultation, so they should be offered a record in writing (which could take the form of a copy of a letter to their GP) or on audiotape. Patients must be offered copies of letters written about them to their GPs.

Patients should receive both individual support and guidance from members of the multi-disciplinary team (MDT) and well-produced information leaflets.\(^2\) They should be encouraged to return to MDT members for additional information and clarification when they want it. Written information should be consistent across each network.

Patients should be given an outline of their overall treatment plan as soon as the necessary clinical decisions have been made, and told of the probable and potential time-scales. Clinicians should not seek to minimise the impact of the treatments they offer, nor the length of time required for recovery from treatment. They should do their best to explain clearly what is happening at each point in the patient’s

---

\(^2\) Sources of information for patients with cancer can be found on the NHS Direct website at: <www.nhsdirect.nhs.uk> telephone advice is available from NHS Direct on 0845 4647.
journey, to be honest about uncertainty and the risk that 
treatment might do more harm than good, and to make sure 
the patient understands when treatment can only be expected 
to produce temporary remission.

When English is not the patient’s first language, somebody 
who speaks the patient’s language should be available to 
facilitate communication. Providers should not normally 
expect members of the patient’s family to act as interpreters.

Information offered to patients should include:

- Sufficient information about basic anatomy and 
  pathology for patients and their carers to understand the 
  disease and how it might affect them;
- Realistic information about the disease and the range of 
  individual variation in its impact and rate of 
  progression;
- The aims, risks and likely effects of proposed 
  diagnostic procedures. Each procedure should be 
  explained to the patient before it is undertaken;
- Balanced information with clear explanations about 
  potential treatment options, including the probability of 
  improved survival or symptom reduction (and 
  uncertainties about benefits), known risks and potential 
  short- and long-term adverse effects;
- Information about other potential effects of the illness 
  and its treatment on both patients and carers, such as 
  anxiety and depression;
- The likelihood of long-term continuing contact with the 
  haematological cancer team;
• Reasons for not offering interventions which patients might anticipate.

Patients should also be given clear information about the hospital service. This should include:

• A description of the way the clinics and doctors function together;
• The way the appointments system operates;
• The names of members of the MDT responsible for managing the patient, and their different responsibilities;
• Contact details for people with whom patients or carers can talk if they feel concerned about any aspect of the illness, treatment, or hospital service.

All health professionals involved with each patient should know what information has been given to the patient. A record of this, along with the patient’s preferences for information and involvement in decision making and a comprehensive summary of the management plan, should be included in the notes. This information should also be given to the patient’s GP within 24 hours so that primary care staff can provide additional support for patients and carers.

**Fertility issues**

Each network should agree policies on fertility issues. These should include training for clinical nurse specialists in counselling patients who could lose their fertility after treatment, and arrangements for cryopreservation of sperm. Whenever possible, patients of reproductive age should have

---

specialist advice on the implications of treatment for their fertility before treatment begins.

Practical and social support

Haematological malignancies often cause long periods of illness, during which many patients are dependent on benefits. Nurse specialists, primary care and palliative care teams all have important roles in co-ordination with social services to ensure that the needs of both patients and carers are identified and met. Patients and carers should be given information about sources of help, such as local and national services and support groups and disability and benefits helplines, both verbally and in writing. Advice on benefits and help with application forms should be available from someone who is familiar with the benefits system.

Nutritional and dietetic support

Intensive treatment for haematological cancers causes problems with nutrition. This issue is particularly important for patients who may remain in hospital for weeks or months at a time. Providers should ensure that patients receive specialist dietetic and nutritional support and high-quality food that meets their individual needs and is acceptable in the context of their ethical or religious beliefs. Dietetic support should also be available after discharge, if required.

Physiotherapy and occupational therapy

Haematological cancer and its treatment can cause disability, fatigue, weakness and loss of muscle, reduced exercise tolerance, pain and respiratory disorders. Patients should have access to specialist physiotherapists and occupational therapists who understand the disease process and can provide appropriate and effective care, e.g. aids and
adaptations; advice on coping with the practical elements of disability.

B. Anticipated benefits

Provision of patient-centred, holistic care and clear and timely information can help patients to cope with their disease, enhance satisfaction with services, and reduce criticism and complaints. Information has a variety of benefits for cancer patients, particularly anxiety reduction, improved ability to cope with treatment and better self-care.

Good communication – particularly sensitive delivery of bad news – is appreciated by patients and leads to greater satisfaction with care. But improving communication skills also benefits doctors, enhancing job satisfaction and reducing stress. Effective communication tends to heighten awareness of the various needs - whether medical, practical, physical or psychological - of patients and carers, and increase the probability that these needs can be met.

C. Evidence

Note: the reliability and quality of evidence supporting the recommendations is graded as A, B and C, where A is the strongest evidence. The grading taxonomy is explained in Appendix 2.

To inform this guidance manual, the National Cancer Alliance (NCA) used focus group discussion and written submissions to explore the feelings and experiences of patients who had been treated for haematological cancers. The NCA report shows that health care professionals often fail to provide the information that patients want and that

---

many are not honest about the likely effects of treatment on patients’ lives.

Patients reported that they would have liked to know how long the full course of treatment would take, and what it might involve, early on in the process. Clinicians tended to minimise the impact of treatment, using phrases like “a bit of radiotherapy” when referring to daily treatment over a month. A patient who reported being told by her consultant that, “‘We might do a bit of a transplant,’” said, “That ‘bit of a transplant’ has taken a year out of my life and I would like to have known before.”

In the focus group, patients explained that they needed information about treatment effects, duration and potential consequences in order to prepare themselves for the ordeal ahead, plan their lives, and arrange for support for the whole course of their cancer journey. All said that a copy of their treatment plan would have been helpful.

Several patients mentioned problems with hospital food and with inadequately trained nurses on non-specialist wards.

The National Patient Survey suggests that there may be particular problems with information for patients with non-Hodgkins lymphoma (NHL). These patients were more likely to report that they did not completely understand the diagnosis than were patients with common solid tumours (30% versus 17% for all patients), less likely to understand the purpose of diagnostic tests (65% understood, versus 75% of all patients), and less likely to realise that different types of treatment were available (59% versus 66%). 25% of patients did not completely understand the purpose of their treatment and 32% did not know how well their treatment had gone.

---

18% would have preferred more information about the outcome of their treatment. (C) There appear to be few high-quality research studies focusing specifically on non-medical issues or psychosocial interventions for patients with haematological cancers. Evidence reviews carried out for previous documents in this series are, however, relevant. Summaries of studies showing patients’ desire for clear information, the need for health service professionals to have specific training in communication skills, and patients’ continuing need for psychological, social and practical support, are available in the *Improving Outcomes* series.\(^7\)

The review did not assess studies describing the specific role of clinical nurse specialists in haematological cancer. There are studies of such nurses working with patients with other types of cancer, notably breast; this role was, after all, developed in the context of breast care services. It seems that care from specialist nurses is generally valued by patients, and that contact with such nurses can improve both physical and emotional well-being of patients. (A)

An analysis of the working practices of three cancer support nurses in the UK describes their role and the types of problem with which they assist. They report that psychological morbidity and social isolation are particularly common among patients with cancer. Cancer support nurses facilitate good communication amongst those responsible for delivering care and ensure a prompt response to patients’ needs. (B)

A report of a small uncontrolled observational study of an emotional support course (“Taking Control”) for patients with haematological cancer suggests that the majority of

---

7 *Improving outcomes in breast cancer* and *Improving outcomes in urological cancers* are available on the NICE website <www.nice.org.uk>; earlier documents dealing with other common cancer sites can be found at: <www.doh.gov.uk/cancer>
participants responded very positively. Although a minority (about 10%) reported some discomfort – usually because they had to face information that they had not wanted to acknowledge – most found that the course helped them to cope emotionally with their situation and helped them to think more positively. Meeting others with haematological cancer on the course helped them to ‘feel normal’. Fifteen of the 26 participants who completed the post-course questionnaire said that what they had learnt had been translated into behavioural changes.(B)

Where structured interventions such as this are not available, support groups can facilitate interaction between patients with cancer. But fewer than half of the NHS patients with NHL who took part in the National Patient Survey were told about support or self-help groups.  

An older (1983) study reported on two small randomised controlled trials (RCTs), run concurrently with patients with Hodgkin’s lymphoma. One compared the effects of written educational material about the disease (a booklet and newsletters) with no educational material and found that patients’ knowledge was improved by the intervention. This was associated with additional benefits including significantly reduced anxiety and fewer treatment problems. The other RCT assessed the effects of participation in eight meetings with a peer support group designed to stimulate discussion, which was attended by an oncologist, psychologist and social worker who took non-directive roles. The peer support group did not appear to produce any significant benefits.(A)

Telephone services that allow patients with cancer (or their carers) to get help and advice with the problems they face at home are appreciated and can be successfully run by trained

---

oncology nurses. (B) The majority of calls are for information and are fairly short; only a minority require further action.

These studies suggest that information is beneficial for patients but that talking about problems without being offered solutions is not helpful.

A longitudinal uncontrolled study, which included 22 leukaemia patients who received psychotherapeutic interventions including training in coping strategies and stress management, found significant decreases in anxiety and depression. (B) However, it is not possible to judge the effectiveness of the various components of what appears to be a complex intervention.

An RCT from the US comparing “treatment as usual” with therapist support, relaxation and imagery training and cognitive-behavioural therapy for 94 patients with haematological cancers undergoing bone marrow transplantation reported no significant differences in outcomes between the interventions. No meaningful comparisons were made between “treatment as usual” and the various psychotherapeutic interventions so it is not possible to judge their effectiveness. (B)

Various other authors describe psychotherapy services and interventions for patients with haematological cancers, but none provides reliable information on their effectiveness or appropriateness. (B) They appear to assume that such interventions are worthwhile.

There is a substantial body of research dealing with communication, information, psychotherapeutic and other non-medical aspects of care for patients with cancer. This literature does not focus specifically on the needs of patients with haematological cancers but the findings may be generalised to this group. Reviews of these aspects of
patient-centred care are summarised in other documents in the *Improving Outcomes* series, available on the NICE and Department of Health websites, and in *Improving Supportive and Palliative Care for Adults with Cancer*, soon to be published by NICE. A clear, evidence based discussion of communication skills and how they may be acquired has recently been published in the *British Medical Journal*.  

D. Measurement

**Structure**

- Availability of clear information for patients in appropriate forms and languages, about their disease, proposed treatment and how its effects might be managed, the hospital and MDT responsible for their care, and any services and sources of support that are likely to be appropriate.

- Clinical nurse specialists who have had training in counselling patients with haematological cancer.

- Facilities and expertise for counselling patients about fertility issues.

- Facilities and support for patients’ mutual support groups.

**Process**

- Attendance by senior clinicians (including consultants) at training courses in communication skills.

---

9 Maguire P, Pitceathly C. Key communication skills and how to acquire them. *BMJ* 2002;325:697-700.
• Private rooms used for crucial meetings between health care staff and patients (in particular, consultations at which patients are given bad news).

• Audit of information offered when:
  - The patient is given bad news;
  - The patient is to undergo a potentially unpleasant diagnostic procedure;
  - Decisions need to be made about treatment;
  - The patient is about to start a course of treatment.

• The application of Trust guidelines on obtaining and documenting informed consent may facilitate the audit of process within networks.

• Audit of patients’ and carers’ experience of psychological support by suitably trained staff from the time of diagnosis and at each subsequent stage of their journey through the illness.

• Evidence that every patient has access to a named nurse specialist who knows about his or her condition, who offers advice and can arrange meetings with appropriate health or social services staff when required.

• Audit of the proportion of staff involved in direct patient care who have had specific training in communication and counselling skills.

• Record of discussion with patients of information given and patient’s involvement in decision-making about care.
• Evidence of effective user involvement.

• Audit of assessment for, and provision of, physical, practical and social support.

**Outcome**

• Providers should carry out surveys of patients’ experience to assess the adequacy of each component of patient-centred care. This should include the following:
  
  - Patients’ knowledge about resources relevant to them;
  
  - Their views on information they were given and the way it was communicated;
  
  - Whether they felt able to participate (if they wished to do so) in choosing between treatment options;
  
  - Whether patients felt that they had been offered sufficient information to give informed consent to each intervention;
  
  - Quality of care and pain control;
  
  - Adequacy of nutritional support and food available, especially for patients with eating problems;
  
  - Waiting times;
  
  - Adequacy of support for patients in their homes (occupational therapy);
  
  - Transport arrangements.
E. Resource implications

Additional resources may be necessary for the provision of high-quality information and educational material for patients and carers, and to allow staff time and facilities for talking with patients and carers.

Resources will be required for training, both for clinical nurse specialists and to improve the communication skills of other health professionals, including senior medical staff.

The main costs of improving patient-centred care in line with these recommendations will be for training and employing more clinical nurse specialists. It is estimated that about four new posts will be required per typical cancer network serving 1.5 million people – altogether, around 140 additional clinical nurse specialists for England and Wales, at an estimated total cost of £4.6 million (see Appendix 1, Economic implications of the guidance).
3. Diagnosis and evaluation

This chapter has been updated and replaced by the recommendations on specialist integrated haematological malignancy diagnostic services (SIHMDS) in the 2016 update of this guideline.
4. Organisation of specialist services

A. Recommendations

**Commissioning services for haemato-oncology**

Service commissioning should be carried out in a co-ordinated way, using specific mechanisms which involve all relevant commissioning bodies. Commissioners should establish explicit organisational arrangements which identify those responsible for overseeing the introduction and adoption of these recommendations. Commissioners will need to conduct baseline assessments of current provision and, using this guidance, set priorities and develop proposals for local implementation.

Commissioners should carefully review services to ensure that patients have access to each form of treatment in the following categories:
<table>
<thead>
<tr>
<th>Low- to intermediate-intensity chemotherapy</th>
<th>All other chemotherapy not included in the definitions below.</th>
</tr>
</thead>
</table>
| High-intensity chemotherapy                | Chemotherapy that is anticipated to result in severe neutropenia \((0.5 \times 10^9/\text{litre or lower})\) for 7 or more days. Other potential organ toxicities, comorbidities and frailty should also be considered. The relevant chemotherapy regimens are usually but not exclusively those used for curative treatment of:  
  - acute myeloid leukaemia  
  - high-risk myelodysplastic syndrome  
  - acute lymphoblastic leukaemia, Burkitt lymphoma (and other rare aggressive lymphomas treated on Burkitt lymphoma like protocols)  
  - lymphoblastic lymphoma.  
Salvage treatments for other types of lymphoma would not usually be included in this definition. |
| Autologous and allogeneic haematopoietic stem cell transplantation (HSCT) | Previously referred to as high-dose therapy in the original 2003 NICE guidance on improving outcomes in haematological cancers. Commissioned centrally through specialised commissioning and a centre should meet FACT-JACIE accreditation standards. |
Multi-disciplinary teams

Clinical services for patients with haematological cancers should be delivered by multidisciplinary haemato-oncology teams.

Haemato-oncology MDTs should serve a population of at least 500,000 people.

Every patient with any form of haematological cancer (as defined by current WHO criteria) should be cared for by a haemato-oncology MDT. [2003, amended 2016]

All patients should have their care discussed in formal MDT meetings attended by members involved in the diagnosis, treatment, or care of that particular patient, and all the clinicians in the MDT should regularly treat patients with the particular forms of haematological cancer with which that MDT deals. [2003, amended 2016]

These MDTs should be responsible not only for initial recommendations about what treatment should be offered, but also for delivery of treatment and long-term support for patients. [2003, amended 2016]

Individual clinicians should be responsible for discussing the MDT’s recommendations with their patients, who should have the opportunity to be informed of the outcome of MDT meetings.

Clinicians who are not members of the MDT should refer any patient with suspected or previously diagnosed haematological cancer to an appropriate haemato-oncology MDT. [2003, amended 2016]

Written referral policies should be disseminated both within hospitals (particularly to departments such as gastroenterology, dermatology, rheumatology and medicine
for the elderly) and to primary care teams, to promote prompt and appropriate referral.

**Core members of haemato-oncology MDTs**

Each haemato-oncology MDT must include sufficient core members for the following people to be present in person or remotely (for example via video conferencing) at every meeting:

- **Haematologists**
  - At least two who specialise in each tumour type being discussed at that meeting (e.g. leukaemia or lymphoma). At least one from each hospital site contributing to the MDT;

- **Haematopathologist**
  - At least one haematopathologist from the SIHMDS should be present; to provide the diagnostic information [new 2016];

- **Nurses**
  - At least one clinical nurse specialist, also ward sisters from hospitals which provide high-intensity chemotherapy

- **Palliative care specialist**
  - At least one palliative care specialist (doctor or nurse) who liaises with specialists from other sites. If, because of staff shortages, a palliative care specialist cannot regularly attend MDT meetings, the MDT must be able to demonstrate that it
reviews patients regularly with such a specialist;

- Support staff Staff to organise team meetings and provide secretarial support.

Teams established to manage patients with lymphoma should include the following additional core members, who should be fully and regularly involved in MDT discussions:

- Clinical oncologist At least one;
- Radiologist At least one, who liaises with radiologists at other sites.

Teams responsible for managing patients with myeloma should include at least one radiologist who liaises with radiologists at other sites and is fully and regularly involved in MDT discussions. Teams that care for patients with myeloma should have rapid access to oncologists for palliative radiotherapy, although it is not necessary for clinical oncologists to regularly attend team meetings. [2003, amended 2016]

**Extended team members**

The MDT should include the following extended team members. They do not have to be present at every MDT meeting.

- Clinical member of the transplant team to which patients could be referred
• Microbiologist (especially for patients with leukaemia)
• Pharmacist
• Vascular access specialist
• Registered dietitian
• Orthopaedic surgeon (myeloma MDT)
• Clinical oncologist (myeloma MDT and leukaemia MDT; provision of cranial radiotherapy for patients with acute lymphoblastic leukaemia (ALL) is an important role for a clinical oncologist) [2003, amended 2016]

Other specialists who may be required for specific cases:

MDTs should have access to the following specialists:
• Dermatologist
• Gastroenterologist
• ENT surgeon
• Interventional radiologist
• Renal physician [2003, amended 2016]

Support for patients and carers

All haemato-oncology MDTs should have access to support staff, including:
• Allied health professionals including rehabilitation specialists
Liaison psychiatrist and/or clinical psychologist
Social worker
Bereavement counsellor
Support for patients and carers. [2003, amended 2016]

A clinical nurse specialist should be the initial point of contact for patients who feel they need help in coping with their disease, its treatment or consequences. This nurse should be able to arrange re-admission, clinical review, or meetings between patients and support staff such as those listed above. Networking between nurses with different types of expertise should be encouraged.

**Responsibilities of haemato-oncology MDTs**

Haemato-oncology MDTs should meet weekly, during normal working hours. All core members should have a special interest in haematological cancer and attend MDT meetings as part of their regular work. They should attend at least two thirds of meetings. [2003, amended 2016]

At each meeting the MDT should:

- ensure all new diagnoses have had SIHMDs review and integrated reporting [new 2016]
- establish, record and review diagnoses for all patients with the forms of cancer that fit the team’s definition criteria;
- assess the extent of each patient’s disease and discuss its probable course;

---

work out treatment plans for all new patients and those with newly-diagnosed relapses;

review decisions about treatment, particularly those made in the interval between MDT meetings. This review should cover not only the clinical appropriateness of the treatment but also the way patients’ views were elicited and incorporated in the decision-making process;

discuss the response to treatment, both during therapy and when the course of treatment is complete.

Think about the appropriateness of radiotherapy in the light of the response to chemotherapy;

think about the patients’ other requirements such as palliative care or referral to other services. MDTs should be able to demonstrate effective systems for collaboration with hospital and community palliative care services;

discuss discontinuing treatment. Each MDT should develop a specific process for considering discontinuation of treatment when its effectiveness has become so limited that adverse effects might outweigh potential benefits;

agree dates for reviewing patients’ progress;

discuss clinical trials and audit results. [2003, amended 2016]

The MDT should:

review all SIHMDS reports of borderline conditions such as aplastic anaemia and other non-malignant bone marrow failure syndromes (which overlap with
hypoplastic myelodysplastic syndrome), and lymphocyte and plasma cell proliferation of uncertain significance (which overlap with lymphoma and myeloma) [new 2016]

- identify requirements for staff and facilities for any form of treatment it provides

- liaise with primary care teams, palliative care teams, services for the elderly and voluntary organisations such as hospices

- ensure that adequate information, advice and support is provided for patients and their carers throughout the course of the illness

- ensure that GPs are given prompt and full information about the nature of their patients’ illness or treatment, any changes in management, and the names of individual MDT members who are primarily responsible for their patients’ management

- record, in conjunction with the cancer registry, the required minimum dataset for all cases of haematological cancer within its specified catchment area, including those cared for by clinicians who are not haematono-cology MDT members

- identify the training needs of MDT members and make sure these needs are met

- be involved in clinical trials and other research studies

- collaborate in planning, and collecting data for audit.

One member of each team, usually the lead clinician, should act as the administrative head of the team, taking overall responsibility for the service it delivers.
Lead clinicians from all haemato-oncology teams in each MDT should collaborate to develop and document evidence-based clinical and referral policies which should be consistently applied across the MDT as a whole. They should agree process and outcome measures for regular audit. All teams should be involved in audit and clinical trials. [2003, amended 2016]

There should be an operational policy meeting at least once a year at which each MDT discusses its policies and reviews the way it functions.

**Maximising the effectiveness of MDT meetings**

Suitable facilities should be provided to support effective and efficient team working. In addition to basic physical facilities such as adequate room and table space, there should be appropriate equipment, for example to allow the group to review pathology slides and imaging results.

Every MDT meeting should have a designated chairperson. Whilst this may be the lead clinician, teams should consider rotating the role of chairperson between members. Teams should aim for an egalitarian mode of interaction, to facilitate open discussion to which all members feel able to contribute.

Each MDT should have named support staff who take the roles of team secretary and co-ordinator. Since these roles overlap, one person may be able to cover both functions in smaller teams. If a team decides that a clinical nurse specialist should be responsible for co-ordinating meetings, secretarial and administrative support should be provided for this nurse. [2003, amended 2016]

The team co-ordinator should arrange meetings, inform all those who are expected to attend, and ensure that all information necessary for effective team functioning and
clinical decision-making is available at each meeting. This will include a list of patients to be discussed and the relevant clinical information, along with diagnostic, staging, and pathology information.

The secretary should take minutes at all meetings, and record and circulate decisions made by the team within the casenotes and both to MDT members and to those others identified as appropriate for routine circulation by the MDT, such as GPs, who may require this information. Confidentiality dictates that these records go to relevant clinicians only.

A designated member of the team’s support staff, working with the administrative head of the team, should be responsible for communication with primary care, palliative care, and other site-specific MDTs. [2003, amended 2016]

Local services

Local services should be developed around MDTs which include at least three haematologists whose sole or main specialist interest is in haemat-oncology.

Teams should specify which patients they can treat locally and make specific arrangements for the delivery of clinical services which they do not provide.

All in-patients undergoing intensive forms of treatment such as complex chemotherapy under the care of this team should be treated either at one hospital, or, where there is a locally agreed case for providing this service at more than one hospital, in hospitals which then each must independently meet the full criteria for the safe delivery of these treatments (summarised in Table 4).

Each haemat-oncology MDT which provides high-intensity chemotherapy should have facilities (as specified in section
1.2 of the short version and section 3.1 of the addendum) and should be able to demonstrate adequate arrangements for 24-hour cover by specialist medical and nursing staff. These arrangements should be sufficiently robust to allow cover for holidays and other absences of team members. [2003, amended 2016]

All hospitals which give high-intensity (non-transplant) chemotherapy for induction or re-induction of remission, or consolidation, or which are likely to admit patients undergoing chemotherapy as medical emergencies, should have documented clinical policies, agreed with haematology and oncology staff, which clearly specify arrangements for the care of such patients. [2003, amended 2016]
5. Treatment (excluding high dose therapy)

A. Recommendations

Recommendations in this chapter on treatment (excluding high-dose therapy) have been reviewed and amended as part of the 2016 update. Recommendations in this chapter on treatment for specific forms of haematological cancer and for management of complications of chemotherapy have been deleted, as they are covered in the NICE guidelines on myeloma and non-Hodgkin’s lymphoma.

Information about treatment in this section is intended to be used as service guidance; the recommendations should not be taken as clinical guidelines. Networks should agree detailed clinical guidelines and update them regularly, using the best available evidence and any specific guidance from the National Institute for Clinical Excellence (NICE). Treatment provided should be audited against these guidelines.

Treatment requirements

Facilities necessary for provision of intensive chemotherapy

Table 4. Summary of Standards necessary for all Units providing induction therapy for acute leukaemia or aggressive lymphoma, and other patients likely to have prolonged neutropenia.
### Table 4a  Facilities

Ensure that there is provision for direct admission to the haematology ward or other facilities equipped to rapidly assess and manage potentially life-threatening complications of chemotherapy (such as neutropenic sepsis or bleeding) in adults and young people, according to agreed local protocols. [2016]

Ensure that there are specific beds in a single dedicated ward within the hospital with the capacity to treat the planned volumes of patients. [2016]

Ensure that there is a designated area for out-patient care that reasonably protects the patient from transmission of infectious agents, and provides, as necessary, for patient isolation, long duration intravenous infusions, multiple medications, and/or blood component transfusions. [2016]

Ensure that there is rapid availability of blood counts and blood components for transfusion. [2016]

Central venous catheter insertion should be performed by an experienced specialist. [2016]

Ensure that there are on-site facilities for emergency cross-section imaging. [2016]

Ensure that cytotoxic drug reconstitution is centralised or organised at the pharmacy. [2016]

### Table 4b  Staffing

| Haematology units that care for adults and young people who are receiving high-intensity chemotherapy |
should have consultant-level specialist medical staff available 24 hours a day. This level of service demands at least three consultants, all full members of a single haematology multidisciplinary team (MDT) and providing in-patient care at a single site. [2016]

- Cover in haematology units that care for adults and young people who are receiving high-intensity chemotherapy should be provided by specialist trainees and specialty doctors who are:
  - Haematologists or oncologists
  - Involved in providing care to the patients being looked after by the centre
  - Familiar with and formally instructed in the unit protocols. [2016]

In haematology units that provide care for adults and young people who are receiving high-intensity chemotherapy:

- there should be adequate nursing staff to provide safe and effective care [new 2016]
- the 2003 NICE cancer service guidance on improving outcomes in haematological cancers recommended that ‘The level of staffing required for neutropenic patients is equivalent to that in a high dependency unit’. [2003]

Nursing staff in haematology units that care for adults and young people who are receiving high-intensity chemotherapy should be competent to care for people
with a severe and unpredictable clinical status. The nursing staff should be able to deal with indwelling venous catheters, recognise early symptoms of infection, and respond to potential crisis situations at all times. [new 2016]

Haematology units that care for adults and young people who are receiving high-intensity chemotherapy should have access to consultant-level microbiological advice at all times. There must be ready access to specialist laboratory facilities for the diagnosis of fungal or other opportunistic pathogens. [2016]

Haematology units that care for adults and young people who are receiving high-intensity chemotherapy should have access to a consultant clinical oncologist for consultation, although radiotherapy facilities do not need to be on site. [2016]

Haematology units that care for adults and young people who are receiving high-intensity chemotherapy should have access to on-site advice from a specialist haematology pharmacist. [2016]

Haematology units that care for adults and young people who are receiving high-intensity chemotherapy should have dedicated clinical and administrative staff to support patient entry into local and nationally approved clinical trials and other prospective studies. [2016]

**Table 4c   Clinical Support**

| Ensure that there is on-site access to bronchoscopy, intensive care and support for adults and young people |
with renal failure. [2016]

<table>
<thead>
<tr>
<th>Haematology units that care for adults and young people who are receiving high-intensity chemotherapy should have written policies for:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• all clinical procedures <strong>and</strong></td>
</tr>
<tr>
<td>• communication with the person’s GP and other teams involved in treatment. [new 2016]</td>
</tr>
</tbody>
</table>

| Haematology units that care for adults and young people who are receiving high-intensity chemotherapy should ensure that there is participation in audit of process and outcome. [2016] |
6. High dose therapy

A. Recommendations

This chapter has been deleted, as high-dose therapy is now covered in the NICE guidelines on myeloma and non-Hodgkin’s lymphoma.
7. Continuing management

A. Recommendations

Most forms of haematological cancer follow a chronic relapsing course, so patients need regular monitoring. There is no reliable evidence on what form of monitoring is most appropriate, or what the optimum intervals between clinic visits might be. Local clinical policies should be agreed by all the haemato-oncology multidisciplinary teams (MDTs) within each network.

The progress of haematological cancer is generally assessed by blood tests, often including ongoing cytogenetic testing. Molecular follow-up is increasingly used for chronic myeloid leukaemia (CML) and acute leukaemia. In lymphoma, CT scans may also be required.

Long-term follow-up

This document does not deal with follow-up for people treated for haematological cancer as children or adolescents; this issue should be covered in forthcoming National Institute for Clinical Excellence (NICE) guidance on child and adolescent cancers.

Patients should be informed that routine long-term follow-up does not offer any clinical advantage to them. Those whose disease is believed to be cured should normally be discharged, but long-term follow-up by telephone or written questionnaire should be considered. The primary aim of such
Long-term follow-up should be to identify and collect information on delayed effects of treatment. Since it is not possible to be certain whether a permanent cure has been achieved, patients should be given clear written instructions on whom they should contact if they are concerned about any new symptoms. They should be given information about the level of risk of recurrence of their disease and reassured that relapse is rare after five years’ freedom from signs of disease. Patients and their GPs should also be given information about the risk of delayed adverse effects of treatment, and symptoms that should prompt contact with the haematological cancer MDT.

Long-term problems are particularly common after high dose treatment and allogeneic bone marrow transplantation (BMT). Providers may therefore consider establishing long-term follow-up systems for patients who have undergone this procedure. Follow-up may also be valuable for collection of information on long-term outcomes of treatment in people who participated in clinical trials.

A database should be maintained to record information about all patients who have undergone treatment for haematological cancer, whether or not they are being actively followed up. There is an increased risk of a variety of cancers after intensive treatment for haematological malignancies, especially among those who were treated as children or adolescents. One particular cause for concern after extended field radiotherapy for Hodgkin’s lymphoma is the high rate of breast cancer in relatively young women. Patients who have had radiotherapy to the neck should have regular thyroid function tests.
B. Anticipated benefits

Since follow-up offers no clinical benefit for asymptomatic patients who appear to be cured, discharging such people allows clinic time to be used for others whose need is greater. A database of information about patients who have undergone treatment for haematological cancer will both improve knowledge of long-term epidemiology and permit patients to be recalled if new evidence emerges on delayed effects of treatment; such a database could be efficiently maintained through postal or telephone contact.

C. Evidence

Note: the reliability and quality of evidence supporting the recommendations is graded as A, B and C, where A is the strongest evidence. The grading taxonomy is explained in Appendix 2.

Effectiveness of follow-up

There is no reliable evidence showing that intensive follow-up of patients who have completed treatment for any form of haematological cancer is beneficial.

The risk of recurrence of Hodgkin’s lymphoma is highest in the first two years after initial treatment. Recurrence can be identified through regular physical examination, blood counts, x-rays for those who had disease in the chest, but there have been no comparative studies to show whether this improves long-term outcomes. Retrospective studies suggest that educating and informing patients so that they recognise sinister symptoms and seek prompt attention may be more useful than routine follow-up, since most recurrences are detected by patients themselves.(B)
In leukaemia, relapse is usually signalled by changes in the blood; the evidence does not support routine use of more invasive procedures such as bone marrow aspiration or lumbar puncture for detecting recurrent disease. (B)

In patients who have been treated for non-Hodgkin’s lymphoma (NHL), physical examination and measurement of serum lactate dehydrogenase (LDH) can be helpful for diagnosing relapse. Imaging may detect a higher proportion of recurrences in low-grade lymphoma but there is no evidence to suggest that this affects survival. (B)

**Long-term effects of treatment**

**Quality of life**

A review of studies suggests that quality of life and health status improves with increasing time since treatment. 80% of long-term survivors of BMT experience good to excellent health. People treated for Hodgkin’s lymphoma may experience persistent side-effects of treatment, with generally poorer physical functioning and more health-related unemployment than age-matched controls; nevertheless, 75-85% of former patients are able to continue in work. (B)

**Secondary malignancies**

Secondary malignancies are recognised long-term adverse effects of treatment for haematological cancers. The incidence of both haematological malignancies and solid tumours is greatly increased among patients who were treated when young; and those who develop secondary cancers are more likely to die from their disease than other cancer patients of the same age. (B)

Risk estimates for secondary haematological malignancies vary widely between patient populations. In general, the risk
of leukaemia is more strongly associated with chemotherapy, especially in patients who had six or more cycles of chemotherapy, who received MOPP, or who were treated for relapse of their primary cancer. Solid tumours are more common after radiotherapy, and usually develop within the treatment field. The excess risk of secondary leukaemia peaks between five and nine years after treatment, but the risk of a secondary solid tumour continues to rise. (B)

Large studies reveal that patients treated for Hodgkin’s lymphoma face about three to seven times the population risk of developing cancer (of any type). The absolute risk for these patients is about 5-7% 10 years after the initial diagnosis, rising to 14% after 20 years. One study reported that 28% of a group of 1253 patients who underwent initial treatment aged 40 or less, had developed a secondary cancer after 25 years of follow-up. (B) However, these patients would have undergone more risky treatment than is normally used today.

The risk of breast cancer among women treated for Hodgkin’s lymphoma depends on their age at the time of their primary disease. Retrospective studies reveal that women treated at 21-30 years old are about six times more likely to develop breast cancer than normal, but among those treated aged 31-40, the risk is 2.4 times normal. A cumulative risk of breast cancer of 16% has been reported at 25 years after treatment. (B)

High dose therapy with allogeneic transplantation for any form of haematological cancer appears to be associated with a similar level of long-term hazard to treatment for Hodgkin’s lymphoma - around four to five times the population risk for any form of cancer. About 1215% of these patients will develop a secondary cancer within 15 years of initial treatment. (B)
D. Measurement

Structure

- Local clinical policies on continuing management of asymptomatic patients with haematological cancer, agreed by all haemato-oncology MDTs in the network.

- Local clinical policies on long-term follow-up of patients whose haematological cancer is believed to be cured.

- Database for recording secondary cancers among people treated for haematological malignancies.

Process

- Audit of local follow-up practice against policy guidelines.

Outcome

- Rates of secondary malignancy after intensive treatment for haematological cancer.

- Patients’ satisfaction with, and comprehension of, information on symptoms that should lead them to contact the haematological cancer MDT.

E. Resource implications

These recommendations are not expected to have significant additional resource implications. Resources will be required to establish and maintain a long-term follow-up database, but no analysis has been carried out of the potential cost.
8. Palliative care

The National Institute for Clinical Excellence (NICE) guidance on improving supportive and palliative care for adults with cancer\(^{11}\) will be published in 2003. It is intended to complement the site-specific guidance, giving detailed recommendations on many issues relevant to this section as they apply to cancer care generally, with supporting evidence. The areas it covers are listed in Topic 2, Patient-centred care.

A. Recommendations

Palliative care services and haemato-oncology should work together to provide integrated care for patients with haematological cancers. These patients need ongoing management by the haemato-oncology multi-disciplinary (MDT) throughout the course of their disease. Adequate palliative care is nevertheless important to maximise quality of life and there should be effective integration between palliative care and haemato-oncology services throughout the patient’s illness, not just when it is acknowledged that the terminal phase has been reached.

Palliative care specialists should be members of haematological cancer MDTs (see Topic 4, Organisation of specialist services). They should take active roles, both as advisors for those who provide direct care for patients on palliation of symptoms such as pain, and working directly with those patients who might benefit from their expertise. Patients and their carers often need multi-faceted support, including information on managing symptoms and help with

\(^{11}\) National Institute for Clinical Excellence. Improving supportive and palliative care for adults with cancer.
accessing social care and benefits. This can be provided by palliative care teams, both in the community and in hospitals.

Palliative care specialists should be involved in discussing the management of patients, especially those for whom the possible survival benefits of treatment might be outweighed by its disadvantages. There should be agreed guidelines for managing the transition from aggressive treatment to palliative care which ensure that it is handled sensitively and appropriately, and that it takes account of individual patients’ emotional and physical needs. This transition should be regarded as a change in treatment goals and emphasis, not a complete handover from haemato-oncology to palliative care services.

**Palliative treatment in haemato-oncology**

Long-term support for patients is part of normal haematology practice and most of the long-term treatment provided for patients with haematological cancers is actually palliative in nature. Blood product support may be necessary at many points in the disease process and it becomes essential to continued survival in the later stages of leukaemia and myeloma. Haemato-oncology MDTs should make arrangements to enable blood product support to be provided to patients in places other than acute hospitals or haematology units.

Some symptom control issues for haemato-oncology patients are the same as for many other malignancies. Pain can be a major problem for some patients. Effective pain control is particularly important for those who undergo intensive treatment and for those with inherently painful diseases such as myeloma. Each haemato-oncology MDT should have access to a pain specialist (who may be the palliative care specialist member of the MDT) who has specific expertise in
the management of the types of problem that patients with haematological cancer may experience. Palliative radiotherapy should be available for patients with bone pain and for those with low-grade lymphomas.

**The specialist palliative care team**

Palliative care is essentially a local service and specialist palliative care teams should be based both in local hospitals and in the community. The role of the specialist palliative care team includes both direct care for patients and families with complex problems, and the provision of advice, support and education for other health professionals. One member of the team should be responsible for ensuring efficient coordination of palliative care services and rapid communication between professionals and with patients and their families.

The specialist palliative care team should include, as a minimum, the following members:

- Palliative care physician;
- Palliative care nurse specialists.

The team should have close links with the following:

- Pain management team;
- Clinical psychologist/liaison psychiatrist;
- Social worker;
- Chaplain/pastoral care worker who can offer counselling and spiritual guidance for patients with advanced incurable illness and their carers;
- Bereavement care worker;
The primary care team.

Those who care for these patients should be able to get advice by telephone from appropriately trained nurses at any time of the day or night. A named member of the palliative care team should be responsible for ensuring effective co-ordination of services to support patients, facilitating both continuity of care and rapid communication between professionals, with patients, and with carers.

The team should endeavour to make it possible for patients to spend their remaining life in the place they prefer, whether this is home, hospital or hospice; but team members should be alert to the possibility that patients’ views about where they would prefer to die may change as death approaches.

Bereavement counselling should be available for carers and close family members, who may become very distressed by an extended period of aggressive treatment which ends with the patient’s death. Some patients and carers may need counselling at the point of transition from attempted cure to purely palliative measures, to help them accept that further aggressive treatment is pointless.

**Palliative care in the community**

Palliative care teams should be available to arrange the provision both of relief from symptoms and social and psychological support for patients living at home whose needs cannot be adequately met by primary care teams. Community palliative care services should work closely with primary care teams and hospital-based services; rapid and effective communication and information-sharing between teams is essential.

Criteria for referral for specialist care should be agreed and documented for the whole cancer network by palliative care
specialists and representatives from primary care and haemato-oncology teams. Primary care teams should assess patients’ needs regularly and accurately, to ensure that patients who require specialist palliative care or treatment are quickly referred to the appropriate MDT.

B. Anticipated benefits

Better integration of palliative care with treatment services throughout the course of the illness can be expected to enhance quality of life for both patients and their carers. Integrated care is particularly essential at the end of life, and the contribution of palliative care specialists can help to create a more appropriate balance between efforts to preserve life and the need for comfort, peace and the support of close family members when it becomes clear that death is inevitable.

C. Evidence

Note: the reliability and quality of evidence supporting the recommendations is graded as A, B and C, where A is the strongest evidence. The grading taxonomy is explained in Appendix 2.

There is weak but consistent evidence that palliative care is used less in haematological cancers than in patients with solid tumours, and that access to specialised palliative care support may have been less available to haematologists than solid tumour oncologists, particularly for patients in the final phase of illness. Much of this evidence originates outside the UK, but whilst it is not clear how similar attitudes here may be to those in the US and Australia (where most studies have been carried out), information from the UK does point to the same conclusions.
The National Cancer Alliance survey carried out to inform this guidance found that few patients had had contact with palliative care teams, but those who had received support from palliative care teams for pain management reported that it had been valuable. This survey did not, however, focus on patients in the terminal phase.

One particular problem with haematological cancer is judging when to stop using intensive forms of treatment; clinicians, patients and their families often find it difficult to acknowledge when remission induction is no longer possible. The decision to change to a palliative approach may be taken too late or not at all, and persistence with aggressive treatment can cause great distress.

A survey based on accounts from carers in the UK bereaved in 1990, found that patients who died of haematological cancer were considerably less likely to receive care from community specialist palliative care nurses in the last months of life than those with other forms of cancer (OR 0.37, p<0.001). These patients are more likely to die in hospital than at home or in a hospice.

A study from the US, based on case-notes of patients who had died of haematological cancer, reported that there was significant variation between doctors in the probability of providing palliative therapy.

There are a few reports of more satisfactory management of the dying process of patients with haematological cancers, but each is based only on one or two cases. Factors that appear to produce better emotional outcomes include early involvement of the palliative care team, whose members may be able to assist the transition from curative to palliative care; reducing use of medical technology and invasive treatment, concentrating instead on the patient’s physical and
psychological comfort; and facilitating dying at home whenever possible. The research suggests that the emotional and spiritual needs of patients and their families are often not recognised and addressed.(C)

A randomised controlled trial (RCT) assessing the effects of improved co-ordination of services for patients dying from a variety of forms of cancer show that this is cost-effective and can improve outcomes for patients. Patients who could contact a co-ordinator who could facilitate access to appropriate services spent significantly less time in hospital or hospice, required significantly fewer home visits by nursing services, and were more likely to receive effective treatment for vomiting.(A)

D. Measurement

Structure

- Availability of palliative care teams to support patients at home or in hospices.
- Availability of telephone support, advice and information services for patients and their carers.
- Availability of bereavement counselling for close family members and carers.

Process

- Audit of involvement of palliative care teams in the management of patients with haematological cancers.
- Evidence that providers elicit information about patients’ preferences about place of death and their views about medical intervention in the terminal phase of illness.
Outcome

- Audit of patients’ experience of pain and satisfaction with pain control during intensive treatment.
- Audit of myeloma patients’ experience of pain and satisfaction with pain control.
- Audit of patients’ and carers’ preferences about place of death.
- Carers’ comments on services provided during the patient’s final month of life.

E. Resource implications

The use of palliative radiotherapy and services for the provision of blood product support are not expected to change significantly under the new guidance. Improving service provision, including the availability of palliative care teams to support patients at home and in hospices and providing bereavement counselling, is likely to have the greatest cost impact. These services provide support to patients with all types of cancer, and is being considered in the context of the NICE guidance on improving supportive and palliative care for adults with cancer, due to be published in 2003.
9. Clinical trials and use of protocols

A. Recommendations

Improvements in the management of haematological cancers (as for solid tumours) require reliable evidence that interventions are effective and that they improve outcomes for patients. It is therefore important that health service commissioners should support the well-designed clinical trials within the National Cancer Research Network (NCRN) portfolio. There should be network-wide co-ordination of local participation in NCRN clinical trials in haematology through each cancer research network. Haemato-oncologists should regularly review the national portfolio of recognised studies and identify those they wish to support at local research network level.

During the period between trials and publication of any National Institute for Clinical Excellence (NICE) appraisal of the interventions assessed, there should be continued support to provide ongoing treatment for patients who took part in the trials.

Multi-disciplinary teams (MDTs) should aim to maximise entry into trials by considering this issue, discussing on-going trials, and reporting on problems and progress at their regular meetings. The possibility of entry into an appropriate trial should be discussed with every patient who fits the inclusion criteria. Such patients should be given accurate and accessible information to inform their decision about whether to participate in the trial (see Topic 2, Patient-centred care).
Trials of treatment for haematological cancer should be designed with outcome measures that reflect quality of life (assessed by patients, not just clinicians) as well as survival time and clinical measures with prognostic significance (surrogate endpoints).

Patients who are not involved in a clinical trial should be treated according to local clinical guidelines based on research evidence.

B. Anticipated benefits

Reliable information on the effectiveness of clinical interventions can only be obtained from large, well-designed trials. Thus, the more patients included in such trials, the better the knowledge base for optimum treatment. Management in the context of trials also tends to be associated with longer survival times for patients with cancer.

In acute leukaemia in particular, survival rates have increased dramatically over the past few decades, especially among young people. This improvement may be directly attributable to knowledge gained from clinical trials.

C. Evidence

Note: the reliability and quality of evidence supporting the recommendations is graded as A, B and C, where A is the strongest evidence. The grading taxonomy is explained in Appendix 2.

In acute leukaemia, the level of participation in multi-centre research studies is high; a majority of eligible patients are currently entered into trials. The same is not true, however, of other forms of haematological cancer; in lymphoma, it is estimated that only about 10% of those who fit the entry criteria for major clinical trials are actually in them. Overall,
perhaps as few as 5% of patients with haematological cancer are treated in the context of a clinical trial.(C)

A systematic review of cancer trials provides some evidence that participation in clinical trials can benefit patients, but it is difficult to distinguish between a real protocol effect from bias due to clinician selection.(A) Audit data from the UK shows that among patients with either acute myeloid leukaemia (AML) or aggressive lymphoma, participation in a trial is associated with a significantly higher chance of complete remission and improved survival.(B) However, patient selection could again account for much of the apparently better outcome. In one of the few studies identified that described outcomes in eligible patients who were not randomised for entry into a trial (of treatment for non-Hodgkin’s lymphoma (NHL)), there was no significant difference in disease-free survival between the groups.(A)

Outcome measures of trials of treatments for haematological cancers are, in almost every case, confined to survival rates and clinical measures that have prognostic value but may not clearly reflect the way patients feel. Since evidence-based decision-making about treatment relies heavily on the results of these trials, it is important that patients’ views of their experience of treatment and its aftereffects should be considered. Reliable and reproducible quality of life measures are available for use in trials of cancer treatment and can have important implications, both for the appropriate use of interventions and so that patients can give truly informed consent to treatment. See Improving Outcomes in Lung Cancer\textsuperscript{12} for a discussion of this issue.

Although the evidence in haematology is far from definitive, treatment in accordance with local clinical guidelines

\textsuperscript{12} Available on the Department of Health website <www.doh.gov.uk/cancer> under the heading Guidance for NHS.
(protocols) is generally associated with better outcomes (see *Improving Outcomes in Breast Cancer*). The development of local protocols demands a critical attitude towards best practice which is likely to have a beneficial effect on those involved. However, further research is required which looks at treatment protocols and outcome in all patients, not just those in trials.

**D. Measurement**

**Structure**

- Network-wide information systems that allow clinicians to identify trials for which specific patients might be eligible.
- Availability of support for clinical trials.
- Availability of continued support for patients who have been successfully treated with products used in clinical trials.

**Process**

- Evidence of regular discussion of participation in clinical trials at MDT meetings.

**Outcome**

- Proportion of patients with each type of haematological cancer entered into trials.

**E. Resource implications**

Treatment in the context of a clinical trial tends to cost more than standard treatment. Adequate resources need to be made

---

13 Available on the NICE website <www.nice.org.uk>, where it is described as “Breast cancer service guidance”.
available, both to support research and to provide appropriate and effective continuing management for patients who have participated in clinical trials. The potential cost impact of these recommendations has not been calculated.
Appendix 1

Economic implications of the guidance

This appendix has been deleted, because the areas it covers have been reviewed and updated since the original economic analysis. The addendum includes the economic analysis carried out for the 2016 recommendations, and the resource impact report considers the resource impact of implementing the recommendations on integrated diagnostic reporting and staffing and facilities.
Appendix 2

How this guidance manual was produced

The manuals in this series are intended to guide health organisations (strategic health authorities, primary care trusts, cancer networks and trusts), their managers and lead clinicians in improving the effectiveness and efficiency of services for patients with cancer. The information and recommendations in the manual are based on systematic reviews of the best available evidence on diagnosis, treatment and service delivery. This evidence is assessed by experts and the recommendations are the product of extensive discussion with leading clinical specialists. The production process is described briefly below; more detail is available in earlier guidance manuals in the series.

The production process begins with a two-day residential event where proposals for improving services for patients with cancer of a specific site (or sites) are generated. A large group of relevant health care professionals, people with personal experience of the particular type of cancer being considered, health care commissioners and academics from around the country, meet to put forward structured proposals based on their experience and knowledge of the research literature. All proposals share a common structure and are intended to improve outcomes for patients. These proposals are then sent to referees, including clinicians, academics, representatives of health authorities, the Department of Health, patient organisations, and relevant charities, many of whom make detailed comments and suggestions. They are also reviewed as part of the process of the National Institute for Clinical Excellence (NICE) and form the basis of the scope of the guidance. Systematic reviews of the research literature, designed to evaluate the proposals, are then carried out or commissioned by the NHS Centre for Reviews and Dissemination (CRD) at the University of York.

This process culminates in the production of two large sources of information, one with a practical or operational focus, and the other containing detailed research evidence on effectiveness. The guidance draws on both these sources, with added input from commissioners, patients, and experts in the particular fields. The writing of the guidance manual is overseen by an editorial group chaired by Professor Bob Haward, accountable to the National Cancer Guidance Steering Group. The writing is undertaken by Dr Arabella Melville, in conjunction with CRD.
Complementary research, designed to quantify the potential cost of major changes in services, is carried out by the School of Health and Related Research at the University of Sheffield. This work involves literature searching, interviews with clinicians and managers, and analyses of costs.

The production of this guidance was funded by NICE, and it has been subject to the full NICE consultation process.

**Evidence grading**

The reliability and quality of evidence which supports the recommendations in the guidance manual is graded throughout the document. The grades are as follows:

A. Evidence derived from randomised controlled trials or systematic reviews of randomised trials.

B. Evidence from non-randomised controlled trials or observational studies.

C. Professional consensus.

The quality of research evidence forms a continuum and there is overlap between these categories. Most of the published research on cancer focuses on clinical evaluations of treatment; little direct research has been carried out on the organisation and delivery of services, issues on which randomised controlled trials (categorised here as the highest quality evidence) may not be feasible. Research designs which might be regarded as of relatively poor quality for evaluating a clinical intervention may therefore be the most reliable available for assessing the organisational issues.

The systematic reviews used to inform the manual are summarised in the document *Improving Outcomes in Haematological Cancers: The Research Evidence*. This document includes details of all the studies to which the manual refers. It is available on the CD-ROM provided with this manual, and is also available in printed format as a CRD report (email: crdpub@york.ac.uk, Tel: 01904-433648).
Appendix 3

People and organisations involved in production of the guidance

3.1 National Cancer Guidance Steering Group

3.2 Participants in the proposal generating event

3.3 People/organisations invited to comment on original proposals

3.4 Researchers carrying out literature reviews and complementary work

3.5 Members of focus groups

Guidance synthesis and writing
Ms A Eastwood Senior Research Fellow, NHS Centre for Reviews and Dissemination, University of York

Professor J Kleijnen Director, NHS Centre for Reviews and Dissemination, University of York

Dr A Melville Independent Consultant

assisted by members of the National Cancer Guidance Steering Group, together with:

Dr R E Clark, Consultant Haematologist, Royal Liverpool Hospital
Dr M H Cullen, Consultant Medical Oncologist, Queen Elizabeth Hospital, Birmingham
Dr A Frater, Director of Public Health, North Hampshire Primary Care Trust
Dr A Jack, Consultant Histopathologist, The General Infirmary at Leeds
Professor P Johnson, Professor of Medical Oncology, Southampton General Hospital
Dr R Johnson, Consultant in Diagnostic Radiology, Christie Hospital, Manchester
Dr S A N Johnson, Consultant Haematologist, Taunton and Somerset Hospital
Professor N H Russell, Professor of Haematology, Nottingham City Hospital
Dr D Swirsky, Consultant Haematologist, The General Infirmary at Leeds
Dr M V Williams, Consultant Clinical Oncologist, Addenbrooke’s Hospital, Cambridge

People/organisations invited to comment on drafts of the guidance
National Cancer Guidance Steering Group
Focus groups
Various professional organisations
Department of Health
NICE Stakeholders; the drafts were subject to the full NICE consultation process

Economic reviews
School of Health and Related Research, University of Sheffield

Project support
The Northern and Yorkshire Cancer Registry and Information Service
Appendix 3.1

Membership of the National Cancer Guidance Steering Group

(This Group, originally established to oversee production of the ‘Improving Outcomes’ programme, also managed its transition to the NICE programme)

**Chairman**

Professor R A Haward  
Professor of Cancer Studies, University of Leeds

**Vice Chairman**

Professor M A Richards  
Sainsbury Professor of Palliative Medicine, St Thomas’ Hospital, London and National Cancer Director

**Members**

Dr J Barrett  
Consultant Clinical Oncologist and Clinical Director, Four Counties Cancer Network

Mrs G Batt  
Section Head, Cancer Policy Team, Department of Health, Wellington House

Mr A Brennan  
Director of Operational Research, School of Health and Related Research, University of Sheffield

Ms A Eastwood  
Senior Research Fellow, NHS Centre for Reviews and Dissemination, York

Dr J Hanson  
Cancer Services Project Co-ordinator, Welsh Office

Dr G Harding  
GP and Medical Director, St John’s Hospice, Doncaster

Professor J Kleijnen  
Director, NHS Centre for Reviews and Dissemination, York

Professor P Littlejohns  
Clinical Director, National Institute for Clinical Excellence

Professor R E Mansel  
Chairman, Division of Surgery, University of Wales College of Medicine, Cardiff

Dame G Oliver  
Director of Service Development, Macmillan Cancer Relief

Mrs V Saunders  
Manager, Northern and Yorkshire Cancer Registry and Information Service

Dr J Verme  
Director, South West Public Health Observatory
Appendix 3.2

Participants in the haematological cancers proposal generating event

Dr J Apperley  Consultant Haematologist, Hammersmith Hospital, London
Professor M R Baker  Director/Lead Clinician, Yorkshire Cancer Network
Ms C Beardmore  Radiotherapy Services Manager, Royal Berkshire Hospital, Reading
Dr S F Beardsworth  Consultant Physician, Castle Hill Hospital, Cottingham
Dr E M Bessell  Consultant Clinical Oncologist, Nottingham City Hospital
Ms R Bratt-Wyton  Clinical Nurse Specialist, Russells Hall Hospital, Dudley
Mrs C Brown  Patient
Mrs M Brown  Nurse Lecturer in Haematology, Thames Valley University
Ms T Burgoyne  Nurse Lecturer/Practitioner in Haematology/Oncology, University of Central England, Birmingham
Dr S Closs  Consultant in Palliative Medicine, Ty Olwen Palliative Care Service, Morriston Hospital
Dr R Cowan  Consultant Clinical Oncologist, Christie Hospital, Manchester
Mrs L Czyzewska  Patient
Dr J Davies  Consultant Haematologist, Western General Hospital, Edinburgh
Ms J Downing  Lecturer in Cancer Care, The Centre for Cancer & Palliative Care Studies, The Royal Marsden Hospital, London
Professor A Faulkner  Professor of Communication in Health Care, Great Barrow, Cheshire
Dr J Ferguson  Clinical Director, South East London Strategic Health Authority
Mr M Geering  Patient
Dr S George  Senior Lecturer in Public Health Medicine,  
             Health Care Research Unit, Southampton  
             General Hospital
Miss V Goode  Nurse Clinician, Christie Hospital,  
              Manchester
Professor B Hancock  Professor of Clinical Oncology, Weston  
                     Park Hospital, Sheffield
Dr A Haynes  Consultant Haematologist, Nottingham City  
              Hospital
Dr J Healey  Consultant Radiologist, Chelsea &  
              Westminster Hospital, London
Dr F Hicks  Consultant in Palliative Medicine, St  
              James’s University Hospital, Leeds
Dr P Hoskin  Consultant Clinical Oncologist, Mount  
              Vernon Hospital, Middlesex
Dr M Howard  Consultant Haematologist, York District  
              Hospital
Ms S Hunton  Director, Bradford Cancer Support Centre
Dr T Illidge  Consultant Clinical Oncologist, Royal South  
              Hants Hospital, Southampton
Dr A Jack  Consultant Histopathologist, The General  
            Infirmary at Leeds
Professor P Johnson  Professor of Medical Oncology,  
                   Southampton General Hospital
Dr C C Kibbler  Consultant Medical Microbiologist, Royal  
               Free Hospital, London
Professor K MacLennan  Professor of Cytopathology &  
                     Histopathology, St James’s University  
                     Hospital, Leeds
Dr A McMillan  Consultant Haematologist, Mount Vernon  
                 Hospital, Middlesex
Dr R Marcus  Consultant Haematologist, Addenbrooke’s  
             Hospital, Cambridge
Dr P Norris  GP, Kingston upon Thames
Dr R Pettengell  Consultant Medical Oncologist, St George’s  
                 Hospital Medical School, London
Mr C Pilmoor  Patient
Professor R Powles  Professor of Haematological Oncology,  
                    The Royal Marsden Hospital, Surrey
Dr A Prentice  Consultant Haematologist, Derriford  
               Hospital, Plymouth
Ms A Ridehalgh  Haematology Clinical Nurse Specialist, The  
                Ipswich Hospital
Mrs J Sale  Patient
Dr S Schey  Consultant Haematologist, Guy’s Hospital,  
             London
Dr C Singer  Consultant Haematologist, Royal United  
             Hospital, Bath
Dr J Spencer  Consultant Radiologist, St James’s University Hospital, Leeds
Mr M Summerhayes  Pharmacist, Guy’s Hospital, London
Dr G Tanner  GP, Bridgwater
Dr B Walker  GP, Seascale
Mr D Watson  Clinical Nurse Manager, Clinical Apheresis Unit, Glasgow Royal Infirmary
Professor J Wilkinson  Professor of Public Health, North East Public Health Observatory

Facilitated by:
Dr J Barrett  Consultant Clinical Oncologist and Clinical Director, Four Counties Cancer Network
Professor R A Haward  Professor of Cancer Studies, University of Leeds
Professor J Kleijnen  Director, NHS Centre for Reviews and Dissemination
Professor M A Richards  Sainsbury Professor of Palliative Medicine, St Thomas’ Hospital, London and National Cancer Director
Appendix 3.3

Referees of the haematological cancers proposals

The guidance was subject to the NICE consultation process (see website www.nice.org.uk for details)

The individuals listed below were also invited by the Developer to act as referees of whom 43% responded.

Dr S Allard  Consultant Haematologist, Northwick Park Hospital, Middlesex
Mr R Anderson  Economic Adviser, Department of Health
Dr B Angus  Senior Lecturer in Pathology, Royal Victoria Infirmary, Newcastle upon Tyne
Dr D Armstrong  Consultant in Public Health Medicine, Guy's, King's and St Thomas' School of Medicine, London
Professor P Armstrong  Professor of Radiology, St Bartholomew's Hospital, London
Dr D Ash  President of the Royal College of Radiologists and Consultant Clinical Oncologist, Cookridge Hospital, Leeds
Dr R Attanoos  Consultant Histopathologist, Llandough Hospital, Penarth
Ms L Baker  Senior Haematology Nurse, Birmingham Heartlands Hospital
Dr M Baker  GP, Lincoln
Mr J J Bannister  Consultant Surgeon, Barnsley District General Hospital
Dr J Barrett  Consultant Clinical Oncologist and Clinical Director, Four Counties Cancer Network
Dr M Bhavnani  Consultant Haematologist, Royal Albert Edward Infirmary, Wigan
Dr N Bienz  Consultant Haematologist, Wexham Park Hospital, Slough
Dr D Black  GP and Chair, Nottingham Clinical Haematology Project
Dr P Blain  Member of the National Cancer Implementation Group
Ms R Bradley  Clinical Nurse Specialist, St Bartholomew’s Hospital, London
Ms R Bratt-Wyton Clinical Nurse Specialist, Russells Hall Hospital, Dudley
Mr A Brennan Director of Operational Research, School of Health and Related Research, University of Sheffield
Ms J Buckham Oncology Services Pharmacist, Sheffield Children’s Hospital
Dr C Bunch Medical Director, John Radcliffe Hospital, Oxford
Mr S Burgess Consultant Obstetrician & Gynaecologist, King George Hospital, Essex
Ms T Burgoyne Nurse Lecturer/Practitioner in Haematology/Oncology, University of Central England, Birmingham
Professor A K Burnett Professor of Haematology, University of Wales College of Medicine, Cardiff
Dr A Byrne Consultant in Palliative Medicine, Holme Tower Marie Curie Centre, Penarth
Ms L Bywater Clinical Nurse Specialist, John Radcliffe Hospital, Oxford
Ms C Cafferty Radiographer, Weston Park Hospital, Sheffield
Dr G Carroll Clinical Director, Eastern Region Specialised Services Commissioning Group, Cambridge
Professor J A Child Consultant Haematologist, The General Infirmary at Leeds
Dr D Clark Consultant Cellular Pathologist, Grantham and District Hospital
Ms H Clements Radiographer, The Churchill Hospital, Oxford
Ms D Coats Senior Cancer Information Nurse Specialist, CancerBACUP
Dr R Coltart Consultant Clinical Oncologist, Kent and Canterbury Hospital
Ms J Connelly Director, Cancer Action Team, St Thomas’ Hospital, London
Dr B Cottier Head of Cancer Services Analysis, National Cancer Services Analysis Team
Dr I Cox GP, Birmingham
Ms S Crofts Haematology & Myeloma Research Nurse, Royal South Hants Hospital, Southampton
Ms D Crowther Chief Executive, Wirral Holistic Care Services
Dr M H Cullen Consultant Medical Oncologist, Queen Elizabeth Hospital, Birmingham
Dr J Cullis Consultant Haematologist, Salisbury District Hospital
Dr P Cumber Consultant Haematologist, West Wales General Hospital
Dr D Cunningham Consultant Medical Oncologist, The Royal Marsden Hospital, Surrey
Ms E Dannie Clinical Nurse Specialist, Hammersmith Hospital, London
Dr P Darragh Deputy Chief Medical Officer, Department of Health, Social Services and Public Safety, Northern Ireland
Ms J Davie Sister, Ninewells Hospital, Dundee
Dr T W Davies Director, East Anglian Cancer Registry, Cambridge
Dr D Deakin Consultant Clinical Oncologist, Christie Hospital, Manchester
Dr S Devereux Consultant Haematologist, King’s College Hospital, London
Professor A K Dixon Professor of Radiology, Addenbrooke’s Hospital, Cambridge
Professor L Donaldson Chief Medical Officer, Department of Health
Ms S Eagle Radiographer, The Royal Marsden Hospital Surrey
Ms A Eastwood Senior Research Fellow, NHS Centre for Reviews & Dissemination, University of York
Dr J Ellershaw Medical Director, Liverpool Marie Curie Centre
Ms M Ellis Bone Marrow Transplant Co-ordinator, John Radcliffe Hospital, Oxford
Dr D Empey Medical Director, The Royal London Hospital
Mr S Evans Chief Executive, The Society of Radiographers
Ms J Fenelon Member of the National Cancer Implementation Group
Dr J Ferguson Clinical Director, South East London Strategic Health Authority
Professor I Finlay Medical Director, Holme Tower Marie Curie Centre, Penarth
Ms A Flory Haematology Sister, Royal Berkshire Hospital, Reading
Dr A Ford GP, Nottingham
Dr A Frater Director of Public Health, North Hampshire Primary Care Trust
Dr J Galloway GP, Kings Lynn
Professor K Gatter Professor of Pathology, John Radcliffe Hospital, Oxford
Professor D George President, British Association of Surgical Oncology
Dr D Gilson Consultant Clinical Oncologist, Cookridge Hospital, Leeds
Dr J Goepel  Consultant Histopathologist, Royal Hallamshire Hospital, Sheffield
Professor J Goldman  Professor of Leukaemia Biology and Chairman, Department of Haematology, Hammersmith Hospital, London
Professor A H Goldstone  Professor of Haematology, University College Hospital, London
Professor E C Gordon-Smith  Professor of Haematology, St George’s Hospital Medical School
Dr H W Habboush  Consultant Haematologist, Nevill Hall Hospital, Abergavenny
Dr R Hall  Chief Medical Officer, Welsh Office
Dr J Halpin  Lead Clinician, Mount Vernon Cancer Network
Professor G W Hanks  Professor of Palliative Medicine, University of Bristol
Dr J Hanson  Cancer Services Project Co-ordinator, Welsh Office
Professor J D Hardcastle  Network Lead Clinician, Mid Trent Cancer Services Network
Dr M Harding  Consultant in Public Health Medicine, Sutton and Merton Primary Care Trust
Mr T Harris  Director, Association of Community Health Councils for England and Wales
Dr C Harrison  Medical Director, Greater Manchester Strategic Health Authority
Dr P Harvey  Consultant Clinical Psychologist, Queen Elizabeth Hospital, Birmingham
Dr C Hatton  Consultant Haematologist, John Radcliffe Hospital, Oxford
Dr V Hempsall  Cancer Lead, Dorset and Somerset Strategic Health Authority
Dr A Hibble  GP, Stamford
Dr N Hicks  Consultant in Public Health Medicine, East Hampshire Primary Care Trust
Professor I Higginson  Professor of Palliative Care and Policy, Guy’s, King’s and St Thomas’ School of Medicine, London
Dr R Hillier  Consultant Physician in Palliative Medicine, Countess Mountbatten House, Southampton
Ms H Hollis  Clinical Nurse Specialist, Royal Berkshire Hospital, Reading
Professor A Horwich  Professor of Clinical Oncology, The Royal Marsden Hospital, Surrey
Dr G Houghton  GP, Birmingham
Dr M Howard  Consultant Haematologist, York District Hospital
Dr P A Hulse  Consultant Radiologist, Christie Hospital, Manchester
Ms S Hunton  Director, Bradford Cancer Support Centre
Professor P G Isaacson  Professor of Histopathology, Royal Free and University College Medical School, London
Sir B Jackson  Former President, Royal College of Surgeons of England
Dr P James  GP, Birmingham
Dr M Jefferson  Consultant in Palliative Medicine, University of Wales College of Medicine
Dr R Johnson  Consultant in Diagnostic Radiology, Christie Hospital, Manchester
Dr S A N Johnson  Consultant Haematologist, Taunton and Somerset Hospital, Taunton
Dr I D A Johnston  Medical Director, University Hospital, Nottingham
Dr A C Jones  Consultant Clinical Oncologist, The Churchill Hospital, Oxford
Dr E Jorge  Former Director of Public Health, Portsmouth and South East Hampshire Health Authority
Ms H Kelly  Radiographer, Royal South Hants Hospital, Southampton
Dr S Kelly  GP, Chichester, West Sussex
Dr P R Kelsey  Consultant Haematologist, Victoria Hospital, Blackpool
Ms V Kelsey  Haematology Clinical Nurse Specialist, Guy’s Hospital, London
Professor D Kerr  Professor of Clinical Oncology, University of Birmingham
Dr N Ketley  Consultant Haematologist, Greenwich District Hospital, London
Dr C C Kibbler  Consultant Medical Microbiologist, Royal Free Hospital, London
Mrs D Knupfer  Executive Director of Nursing, Christie Hospital, Manchester
Dr A Kyle  Consultant Haematologist, Antrim Area Hospital, Belfast
Dr A K Lakhani  Consultant Haematologist, Farnborough Hospital, Orpington
Dr R Lane  Consultant in Palliative Medicine, Dewsbury & District Hospital
Ms E Lardner  Clinical Nurse Specialist, Singleton Hospital, Swansea
Dr A W Lee  GP, Scunthorpe
Dr S Levy  GP, Stockport
Ms C Lewis  Research Nurse, Royal Berkshire Hospital, Reading
Professor D C Linch  Professor of Haematology, Royal Free and University College Medical School, London
Professor T A Lister  Professor of Medical Oncology, St Bartholomew’s Hospital, London
<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor P Littlejohns</td>
<td>Clinical Director, National Institute for Clinical Excellence</td>
</tr>
<tr>
<td>Dr P Lorigan</td>
<td>Consultant Medical Oncologist, Weston Park Hospital, Sheffield</td>
</tr>
<tr>
<td>Mr G McGhee</td>
<td>Senior Staff Nurse, Western General Hospital, Edinburgh</td>
</tr>
<tr>
<td>Dr M McGovern</td>
<td>Senior Policy/Medical Adviser, Department of Health</td>
</tr>
<tr>
<td>Dr I MacLellan-Smith</td>
<td>GP, Cheadle, Cheshire</td>
</tr>
<tr>
<td>Dr A D L MacVicar</td>
<td>Consultant Radiologist, The Royal Marsden Hospital, London</td>
</tr>
<tr>
<td>Professor G McVie</td>
<td>Director General, Cancer Research Campaign</td>
</tr>
<tr>
<td>Dr J Maher</td>
<td>Consultant Clinical Oncologist, Mount Vernon Hospital, Middlesex</td>
</tr>
<tr>
<td>Dr A R Manhire</td>
<td>Consultant Radiologist, Nottingham City Hospital</td>
</tr>
<tr>
<td>Dr I Manifold</td>
<td>Medical Director, Weston Park Hospital, Sheffield</td>
</tr>
<tr>
<td>Professor R E Mansel</td>
<td>Chairman, Division of Surgery, University of Wales College of Medicine, Cardiff</td>
</tr>
<tr>
<td>Dr R Marcus</td>
<td>Clinical Director, British Committee for Standards in Haematology</td>
</tr>
<tr>
<td>Mr I Mark</td>
<td>Consultant Urologist, Lincoln County Hospital</td>
</tr>
<tr>
<td>Dr T S Maughan</td>
<td>Consultant Clinical Oncologist, Velindre Hospital, Cardiff</td>
</tr>
<tr>
<td>Dr G M Mead</td>
<td>Consultant Medical Oncologist, Royal South Hants Hospital, Southampton</td>
</tr>
<tr>
<td>Dr A B Mehta</td>
<td>Consultant Haematologist, Royal Free Hospital, London</td>
</tr>
<tr>
<td>Mrs R Miles</td>
<td>Chair, National Cancer Alliance</td>
</tr>
<tr>
<td>Dr D W Milligan</td>
<td>Consultant Haematologist, Birmingham Heartlands Hospital</td>
</tr>
<tr>
<td>Professor G Morgan</td>
<td>Professor of Haematology, University of Leeds</td>
</tr>
<tr>
<td>Ms C Morris</td>
<td>Sister, Haematology Day Care Unit, Royal Cornwall Hospital, Truro</td>
</tr>
<tr>
<td>Dr T C M Morris</td>
<td>Consultant Haematologist, Belfast City Hospital</td>
</tr>
<tr>
<td>Professor G J Mufti</td>
<td>Professor of Haemato-oncology, Guy’s, King’s and St Thomas’ School of Medicine, London</td>
</tr>
<tr>
<td>Dr S Munday</td>
<td>Director of Public Health, South Warwickshire Primary Care Trust</td>
</tr>
<tr>
<td>Ms M Nendick</td>
<td>Nursing Officer, Department of Health</td>
</tr>
<tr>
<td>Dr G Newman</td>
<td>Consultant Clinical Oncologist, Royal Sussex County Hospital</td>
</tr>
<tr>
<td>Dr P Norris</td>
<td>GP, Kingston upon Thames</td>
</tr>
</tbody>
</table>
Dr A J Norton  Senior Lecturer in Histopathology, St Bartholomew’s Hospital, London
Dame G Oliver  Director of Service Development, Macmillan Cancer Relief
Dr B A Oppenheim  Consultant Microbiologist, Withington Hospital, Manchester
Ms H Outhwaite  Clinical Nurse Specialist, Guy’s Hospital, London
Mrs S Pacey  Pharmacist, Nottingham City Hospital
Dr A Pagliuca  Consultant Haematologist, King’s College Hospital, London
Ms J Palin  Project Manager, Cancer Action Team, St Thomas’ Hospital, London
Dr G Park  GP, Stokesley
Dr M Parmar  Head, Cancer Division, MRC Clinical Trials Unit, Cambridge
Dr H Parry  Consultant Haematologist, Ysbyty Gwynedd, Bangor
Dr J Pawade  Consultant Histopathologist, Bristol Royal Infirmary
Professor M Pearson  Deputy Director of Human Resources, Department of Health
Dr S Pearson  Director of Clinical Strategy, Gloucestershire Hospitals NHS Trust
Ms S Perrett  Macmillan Clinical Nurse Specialist for Haematology, University Hospital of Wales, Cardiff
Dr F Pitt  Consultant in Public Health Medicine, North Sheffield Primary Care Trust
Mrs E Porterfield  Member of the National Cancer Implementation Group
Dr M Potter  Consultant Haematologist, Royal Free Hospital, London
Dr C Poynton  Consultant Haematologist, University Hospital of Wales, Cardiff
Dr A Prentice  Consultant Haematologist, Derriford Hospital, Plymouth
Dr T Priestman  Consultant Clinical Oncologist, New Cross Hospital, Wolverhampton
Dr J Pritchard  Scientific Adviser, Welsh Office
Professor S J Proctor  Professor of Haematological Medicine, Royal Victoria Infirmary, Newcastle upon Tyne
Dr E Pugh  Medical Director, Butterwick Hospice, Stockton-on-Tees
Dr J Radford  Consultant Physician, Christie Hospital, Manchester
Dr S Ramakrishnan  Lead Clinician, Weston Park Hospital, Sheffield
Dr A D Ramsay  Secretary, British Lymphoma Pathology Group, Great Ormond Street Hospital for Children, London

Mr B Rees  Consultant General Surgeon, University Hospital of Wales, Cardiff

Dr P Revell  Consultant Haematologist, Staffordshire General Hospital, Stafford

Professor R H Reznek  Professor of Diagnostic Imaging, St Bartholomew’s Hospital, London

Professor M A Richards  Sainsbury Professor of Palliative Medicine, St Thomas’ Hospital, London

Ms A Ridehalgh  Haematology Clinical Nurse Specialist, Ipswich General Hospital

Ms M Rigge  Director, College of Health

Dr M H Robinson  Senior Lecturer in Clinical Oncology, Weston Park Hospital, Sheffield

Professor P Robinson  Professor of Clinical Radiology, St James’s University Hospital, Leeds

Dr P Roderick  Senior Lecturer in Public Health Medicine, Health Care Research Unit, Southampton

Professor T Rogers  Imperial College Medical School, London

Professor A Z S Rohatiner  Professor of Haemato-oncology, St Bartholomew’s Hospital, London

Dr N Rooney  Consultant Pathologist, Royal United Hospital, Bath

Dr A W W Roques  Consultant Haematologist, Worthing Hospital, West Sussex

Mr R D Rosin  Consultant Surgeon, St Mary’s Hospital, London

Dr J R Y Ross  Consultant Haematologist, Northampton General Hospital

Professor G Rubin  GP, Yarm

Professor N H Russell  Professor of Haematology, Nottingham City Hospital

Dr R D Russell-Jones  Consultant Dermatologist, St Thomas’ Hospital, London

Dr S Schey  Director of Clinical Haematology, Guy’s Hospital, London

Dr E A Scott  Implementation Director, NHS Modernisation Agency

Dr M Sekhar  Consultant Haematologist, West Middlesex University Hospital,

Professor P Selby  Professor of Cancer Medicine, St James’s University Hospital, Leeds

Professor K Sikora  Professor of Clinical Oncology, Hammersmith Hospital, London

Dr C Sinnott  Consultant and Senior Lecturer in Palliative Medicine, St Thomas’ Hospital, London
<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr D N Slater</td>
<td>Consultant Histopathologist/Dermatopathologist, Royal Hallamshire Hospital, Sheffield</td>
</tr>
<tr>
<td>Mr J Smallwood</td>
<td>Lead Cancer Clinician, Southampton General Hospital</td>
</tr>
<tr>
<td>Mr C Smee</td>
<td>Chief Economic Adviser, Department of Health</td>
</tr>
<tr>
<td>Dr A G Smith</td>
<td>Consultant Haematologist, Southampton General Hospital</td>
</tr>
<tr>
<td>Dr M J Smith</td>
<td>Consultant Physician, Heatherwood Hospital, Ascot</td>
</tr>
<tr>
<td>Dr S R Smith</td>
<td>Consultant Haematologist, Torbay Hospital, Torquay</td>
</tr>
<tr>
<td>Dr J Spiby</td>
<td>Consultant in Environmental Public Health, Chemical Incident Response Service, London</td>
</tr>
<tr>
<td>Mr M Stone</td>
<td>Director, The Patient’s Association</td>
</tr>
<tr>
<td>Mrs R Stone</td>
<td>Manager, Hogarth Haematology and Bone Marrow Transplant Unit, Nottingham City Hospital</td>
</tr>
<tr>
<td>Dr N Stuart</td>
<td>Consultant Medical Oncologist, Ysbyty Gwynedd, Bangor</td>
</tr>
<tr>
<td>Mr M Summerhayes</td>
<td>Principal Oncology Pharmacist, Guy’s Hospital, London</td>
</tr>
<tr>
<td>Dr N Summerton</td>
<td>Clinical Senior Lecturer in Primary Care Medicine, University of Hull</td>
</tr>
<tr>
<td>Dr P Sutton</td>
<td>GP, Brigg, North Lincolnshire</td>
</tr>
<tr>
<td>Dr N Sykes</td>
<td>Consultant in Palliative Medicine, St Christopher’s Hospice, London</td>
</tr>
<tr>
<td>Dr G Tanner</td>
<td>GP, Bridgwater, Somerset</td>
</tr>
<tr>
<td>Dr T Tate</td>
<td>Medical Adviser, Marie Curie Cancer Care</td>
</tr>
<tr>
<td>Dr J Thomas</td>
<td>Director of Public Health, Sunderland Teaching Primary Care Trust</td>
</tr>
<tr>
<td>Mrs H Thornton</td>
<td>Chairman, Consumers’ Advisory Group for Clinical Trials</td>
</tr>
<tr>
<td>Mr A Turner</td>
<td>Member of the National Cancer Implementation Group</td>
</tr>
<tr>
<td>Dr P Twentyman</td>
<td>Secretary, United Kingdom Co-ordinating Committee on Cancer Research</td>
</tr>
<tr>
<td>Dr E A Vandenberghe</td>
<td>Consultant Haematologist, Royal Hallamshire Hospital, Sheffield</td>
</tr>
<tr>
<td>Dr J van der Walt</td>
<td>Consultant Histopathologist, St Thomas’ Hospital, London</td>
</tr>
<tr>
<td>Dr J Verne</td>
<td>Director, South West Public Health Observatory</td>
</tr>
<tr>
<td>Dr S Vinnicombe</td>
<td>Consultant Radiologist, St Bartholomew’s Hospital, London</td>
</tr>
<tr>
<td>Name</td>
<td>Position and Affiliation</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------------------------------------------------------</td>
</tr>
<tr>
<td>Dr C Waine</td>
<td>Former Director of Health Programmes and Primary Care</td>
</tr>
<tr>
<td></td>
<td>Development, Sunderland Health Authority</td>
</tr>
<tr>
<td>Mr D Watson</td>
<td>Clinical Nurse Manager, Clinical Apheresis Unit, Glasgow</td>
</tr>
<tr>
<td></td>
<td>Royal Infirmary</td>
</tr>
<tr>
<td>Dr P Watson</td>
<td>Medical Director, Essex Strategic Health Authority</td>
</tr>
<tr>
<td>Dr B Wee</td>
<td>Consultant in Palliative Medicine, Countess Mountbatten</td>
</tr>
<tr>
<td></td>
<td>House, Southampton</td>
</tr>
<tr>
<td>Dr N C West</td>
<td>Consultant Haematologist, West Cumberland Hospital</td>
</tr>
<tr>
<td></td>
<td>Whitehaven</td>
</tr>
<tr>
<td>Mrs K Westbrook</td>
<td>Radiographer, Bristol Royal Infirmary</td>
</tr>
<tr>
<td>Dr B S Wilkins</td>
<td>Senior Lecturer in Pathology, University of Southampton</td>
</tr>
<tr>
<td>Dr M V Williams</td>
<td>Consultant Clinical Oncologist, Addenbrooke’s Hospital,</td>
</tr>
<tr>
<td></td>
<td>Cambridge</td>
</tr>
<tr>
<td>Dr J Z Wimperis</td>
<td>Consultant Haematologist, Norfolk and Norwich Hospital</td>
</tr>
<tr>
<td>Dr H Winter</td>
<td>Senior Lecturer in Public Health Medicine, University of</td>
</tr>
<tr>
<td></td>
<td>Birmingham</td>
</tr>
<tr>
<td>Dr C Wolfe</td>
<td>Reader in Public Health Medicine, Guy’s, King’s &amp; St Thomas’</td>
</tr>
<tr>
<td></td>
<td>School of Medicine</td>
</tr>
<tr>
<td>Dr A Wotherspoon</td>
<td>Consultant Histopathologist, The Royal Marsden Hospital,</td>
</tr>
<tr>
<td></td>
<td>London</td>
</tr>
<tr>
<td>Mr N Young</td>
<td>Chief Executive, Macmillan Cancer Relief</td>
</tr>
</tbody>
</table>
Appendix 3.4

Researchers carrying out literature reviews and complementary work

**Overall co-ordinators**
Ms A Eastwood  
Professor J Kleijnen  
and Dr H McIntosh  
NHS Centre for Reviews and Dissemination,  
University of York

**i) Literature reviews**
Professor P Johnson and Ms B Bennett-Lloyd  
Cancer Research UK Oncology Unit,  
Cancer Sciences Division, University of Southampton School of Medicine  
Barts and the London School of Medicine and Dentistry

Dr S Agrawal  
Health Services Research Unit, Community Clinical Sciences Research Division, University of Southampton School of Medicine

Dr S George

Contributed reviews which were used to inform guidance on Topics 1, 3, 4, 5, 6, and 7.

Miss R Collins and Miss M Womphrey  
NHS Centre for Reviews and Dissemination, University of York

Contributed reviews which were used to inform guidance on Topics 2 and 8.

Ms K Misso and Ms G Ritchie  
NHS Centre for Reviews and Dissemination, University of York

Undertook the literature searches for the review work.
ii) Patient views of haematological cancer services
Ms R Miles and National Cancer Alliance, Oxford
Ms C Smith

iii) Economic review
V Abbott School of Health and Related Research,
R Ara University of Sheffield
M Holmes
C Knight
M Stephenson
S Ward
## Appendix 3.5

### Focus groups: membership

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ms E Andelin</td>
<td>Assistant Director of Patient Services, Bradford City Primary Care Trust</td>
</tr>
<tr>
<td>Professor M R Baker</td>
<td>Director/Lead Clinician, Yorkshire Cancer Network</td>
</tr>
<tr>
<td>Mr M Bellamy</td>
<td>Former Chief Executive, Ealing, Hammersmith and Hounslow Health Authority</td>
</tr>
<tr>
<td>Dr A Benghiat</td>
<td>Cancer Lead Clinician, Leicester Royal Infirmary</td>
</tr>
<tr>
<td>Dr P Bevan</td>
<td>Deputy Director of Public Health, Directorate of Health and Social Care for London</td>
</tr>
<tr>
<td>Mr D Campbell</td>
<td>Chief Executive, Liverpool Central Primary Care Trust</td>
</tr>
<tr>
<td>Dr A Champion</td>
<td>Assistant Cancer Services Project Coordinator, Welsh Office</td>
</tr>
<tr>
<td>Dr I G Cox</td>
<td>Macmillan GP Adviser in Cancer and Palliative Care, Birmingham</td>
</tr>
<tr>
<td>Miss C Edwards</td>
<td>Chief Executive, North Trent Commissioning Network, Barnsley Primary Care Trust</td>
</tr>
<tr>
<td>Mrs S Ellis</td>
<td>Partnership Director, West Yorkshire Primary Care Organisations, Wakefield West Primary Care Trust</td>
</tr>
<tr>
<td>Mr J Grimes</td>
<td>Director of Finance, North &amp; East Yorkshire and Northern Lincolnshire Strategic Health Authority</td>
</tr>
<tr>
<td>Dr J Halpin</td>
<td>Lead Clinician, Mount Vernon Cancer Network</td>
</tr>
<tr>
<td>Dr V Hempsall</td>
<td>Cancer Lead, Dorset and Somerset Strategic Health Authority</td>
</tr>
<tr>
<td>Dr J Kearney</td>
<td>Director of Public Health, Dacorum Primary Care Trust</td>
</tr>
<tr>
<td>Dr A W Lee</td>
<td>GP, Scunthorpe</td>
</tr>
<tr>
<td>Dr M Marshall</td>
<td>Cancer Lead, Middlesbrough Primary Care Trust</td>
</tr>
<tr>
<td>Dr S Munday</td>
<td>Director of Public Health, South Warwickshire Primary Care Trust</td>
</tr>
<tr>
<td>Dame G Oliver</td>
<td>Director of Service Development, Macmillan Cancer Relief</td>
</tr>
</tbody>
</table>
Dr S Pearson  Director of Clinical Strategy, Gloucestershire Hospitals NHS Trust
Dr F A Pitt  Consultant in Public Health Medicine, North Sheffield Primary Care Trust
Mr R J Priestley  Former Chief Executive, North Staffordshire Health Authority
Dr E A Scott  Implementation Director, NHS Modernisation Agency
Dr J Spiby  Consultant in Environmental Public Health, Chemical Incident Response Service, London
Dr J Thomas  Director of Public Health, Sunderland Teaching Primary Care Trust
Dr J Verne  Director, South West Public Health observatory
Dr P Watson  Medical Director, Essex Strategic Health Authority

Facilitated by:
Ms S O’Toole  Consultant in Health Policy and Management

Supported by:
Mrs V Saunders  Manager, Northern and Yorkshire Cancer Registry and Information Service
Appendix 4

Glossary of terms

**Acute**
Sudden or severe, in onset.

**Acute leukaemia**
A rapidly progressive cancer of the blood forming system of sudden onset where immature *white blood cells* proliferate uncontrollably.

**Acute lymphoblastic leukaemia (ALL)**
A type of *acute leukaemia* in which the *white blood cells* produced in excess are immature *lymphocytes* (*white blood cells* formed from lymphoid *stem cells*).

**Acute myeloid leukaemia (AML)**
A type of *acute leukaemia* in which the *white blood cells* produced in excess are immature *granulocytes* or monocytes (*types of white blood cells* formed from myeloid *stem cells*).

**Age-standardised incidence**
A method of more accurately comparing incidence rates between populations by removing differences in the age distributions of those populations.

**Agricultural biocides**
Chemicals that kill organisms e.g. herbicides and pesticides.

**Alkylating agents**
A family of drugs that prevent the division of cancer cells by damaging DNA.

**Allogeneic transplantation/allograft**
A procedure in which a patient receives *bone marrow* or *blood stem cells* from a genetically matched donor following *high dose therapy* to destroy their own *bone marrow*.

**Anaemia**
A condition in which the number of red blood cells in the blood is below normal.

**Antibodies**
Proteins made by *plasma cells* in response to a foreign substance (*antigen*) in the body.
Antigen
Any molecule recognised by the immune system as being foreign and therefore provoking the production of antibodies.

Audit
A method by which those involved in providing services assess the quality of care. Results of a process or intervention are assessed, compared with a pre-existing standard, changed where necessary, then reassessed.

Autologous transplantation/autograft
A procedure in which a patient receives their own bone marrow or stem cells which were collected prior to a course of high dose therapy to destroy their remaining bone marrow. Also see stem cell harvesting.

Axilla
The armpit.

Biopsy
Removal of a sample of tissue or cells from the body to assist in diagnosis of a disease.

Bisphosphonates
Drugs used to slow bone damage caused by myeloma cells, reduce the risk of fractures and reduce bone pain.

Blast crisis
A phase of CML in which the disease progression becomes more rapid and aggressive and the number of immature, abnormal white blood cells (blasts) in the bone marrow and blood is extremely high. Also called the blast or acute phase.

Blood products
Whole blood or components of the blood including red blood cells, platelets and plasma.

Blood stem cells
Progenitor cells which give rise to red blood cells and immune system blood cells.

Bone marrow
The soft inner part of the bone. Bone marrow produces the stem cells which develop into the three different types of blood cells: red blood cells, white blood cells and platelets.
Bone marrow transplantation (BMT)
A procedure to replace bone marrow that has been destroyed by high dose therapy. There are two types of transplant – allogeneic where healthy bone marrow is taken from a donor who has a similar tissue type to the patient and autologous, where the patient's own bone marrow is used.

Cardiology
A branch of medicine concerned with the diagnosis and treatment of diseases affecting the heart and blood vessels.

Central venous catheter/central line
A thin plastic tube which is inserted through the skin into a vein in the chest through which blood tests can be taken and intravenous chemotherapy and blood transfusions can be given. Once in place it can remain in the vein for many months.

Chemotherapy
The use of drugs that kill cancer cells, or prevent or slow their growth.

Chronic
Long-lasting or slowly progressing.

Chronic leukaemia
Generally a slowly progressing cancer of the blood, usually of gradual onset, where the white blood cells present in excess are more mature than those in acute leukaemia. In some types of chronic leukaemia the blood cells are not over-produced but fail to die when they should do.

Chronic lymphocytic leukaemia (CLL)
A type of chronic leukaemia in which the white blood cells present in excess are lymphocytes (white blood cells formed from lymphoid stem cells).

Chronic myeloid leukaemia (CML)
A type of chronic leukaemia in which the white blood cells present in excess are granulocytes (white blood cells formed from myeloid stem cells).

Clinical oncologist
A doctor who specialises in the treatment of cancer patients, particularly through the use of radiotherapy, but may also use chemotherapy.
Cognitive and behavioural therapy
Types of therapy, often delivered by psychologists, usually based on talking and practising specific types of voluntary activity. This group of interventions can include, for example, relaxation training, counselling, and psychological approaches to pain control.

Colony-stimulating factors (CSF)
Substances which stimulate the production of certain blood cells e.g. G-CSF stimulates granulocytes. They may be used to produce extra stem cells prior to a stem cell harvest, or to promote the recovery of white blood cells following chemotherapy.

Combination chemotherapy
The use of more than one drug to kill cancer cells.

Computed tomography (CT)
An x-ray imaging technique.

Conditioning
The elimination of malignant cells by the use of high dose therapy prior to bone marrow or stem cell transplantation.

Core biopsy
The removal of a tissue sample with a needle for laboratory examination. This test uses a slightly larger needle than the one used for fine needle aspiration (FNA) and is usually done under local anaesthetic.

Cranial
Of or relating to the skull.

Cryopreservation
Preservation by freezing.

Cytogenetic abnormalities
Abnormalities of chromosomes.

Cytogenetics
The study of chromosomes and chromosomal abnormalities.

Cytokines
Proteins that are released by cells of the immune system which have specific effects on other cells. Some cytokines help the body to destroy abnormal cells. Examples of cytokine treatment include interferon and interleukins.

Cytotoxic
Toxic to cells. This term is used to describe drugs which kill cancer cells or slow their growth.
**Dermatologist**
A doctor who specialises in disorders of the skin.

**Epidemiology**
The study of populations in order to determine the frequency and distribution of disease and measure risks.

**Epithelial cancers**
Cancers originating in epithelial tissue. This is a membrane-like tissue that lines internal and external surfaces of the body including organs, vessels and other small cavities.

**Erythrocyte sedimentation rate (ESR)**
A test that measures the rate at which red blood cells settle out of suspension in blood plasma. The amount of protein in the plasma may increase as a result of infection or cancer which causes the red cells (erythrocytes) to settle out more quickly than normal.

**Febrile**
Feverish.

**Fibrotic tissue**
Fibrous tissue that replaces normal tissue e.g. scars or tissue that is left after the cancer has been killed by treatment.

**Fine needle aspiration (FNA)**
The removal of cells using a fine needle for examination in the laboratory.

**Gallium scanning**
An imaging technique sometimes used to provide further information about abnormalities identified on plain x-ray or CT scan images.

**Gastroenterologist**
A doctor who specialises in disorders of the digestive system including the liver.

**Graft-versus-host disease**
A serious complication of bone marrow transplantation where the donated bone marrow reacts against the patient’s own tissue.

**Granulocyte**
A white blood cell that is an essential component of the immune system.

**Granulocyte-colony-stimulating factor (G-CSF)**
See colony-stimulating factors.

**Haematological cancers**
Cancers of the blood and blood-forming tissues.
**Haematologist**
A doctor who specialises in disorders of the blood and blood-forming tissues.

**Haematology**
A branch of medicine concerned with the study and treatment of disorders of the blood and blood-forming tissues.

**Haemato-oncology**
A branch of medicine concerned with the study and treatment of cancers of the blood and blood-forming tissues.

**Haemopoietic or haematopoietic**
The process by which blood cells are produced in the *bone marrow*.

**Hepatosplenomegaly**
Abnormal enlargement of both the liver and the *spleen*.

**High dose therapy**
Intensive treatment with *chemotherapy* and/or *radiotherapy* to kill malignant cells in the *bone marrow*. As the treatment also kills healthy *bone marrow* cells, it must be followed by *bone marrow* or *stem cell transplantation*.

**High grade lymphomas**
Faster growing, clinically aggressive *lymphomas*.

**Hodgkin's lymphoma**
A type of cancer in which the cells of the lymph tissue are produced in excess and result in the progressive, painless enlargement of *lymph nodes*, the *spleen* and general lymph tissue. A particular abnormal cell, known as the Reed-Sternberg cell is found in Hodgkin's lymphoma.

**Human Leukocyte Antigen (HLA)**
Comparing the tissue type of patients and potential donors.

**Hypercalcaemia**
Abnormally high levels of calcium in the blood.

**Iatrogenic**
As a consequence of treatment.

**Immunophenotype**
Pattern of specific proteins (*antigens*) present on the surface membrane of blood cells.

**Immunosuppression**
Suppression of the immune system.
**Immunotherapy**
Treatment by stimulating or restoring the body’s own immune system.

**Indolent lymphomas**
*Lymphomas* that grow and spread slowly (also called low grade lymphomas).

**Induction chemotherapy**
The first phase of chemotherapy treatment designed to induce remission.

**Indwelling venous catheters**
See central venous catheters.

**Intrathecal**
Into the fluid around the spine.

**Intravenous (IV)**
Into a vein.

**Kinase inhibitors**
Drugs that interfere with the growth of some cancer cells by blocking the signals that prompt the cancer cells to divide.

**Leukaemia**
Cancer of the blood forming system in the bone marrow, usually characterised by the production of abnormal white blood cells which may be present in the bone marrow and blood.

**Lymphadenopathy**
Disease or swelling of the lymph nodes.

**Lymphocytes**
A class of white blood cell that fights infection and disease by producing antibodies and other protective substances. There are two categories – B cells and T cells.

**Lymphoid cell**
Pertaining to cells involved in lymph or lymphatic tissue.

**Lymphoma**
Cancer of the lymphatic system. There are two main types of lymphoma - *Hodgkin’s lymphoma* and *non-Hodgkin’s lymphoma*.

**Magnetic resonance imaging (MRI)**
A non-invasive method of imaging which allows the form and metabolism of tissues and organs to be visualised (also known as nuclear magnetic resonance).
**Medical oncologist**
A doctor who specialises in the treatment of cancer through the use of *chemotherapy*.

**Meta-analysis**
The statistical analysis of the results of a collection of individual studies to synthesise their findings.

**Microbiologist**
A person who specialises in the study of micro-organisms such as bacteria, viruses and yeasts, who may also be involved in the development of treatment plans for such infections.

**Monoclonal antibody therapy**
*Antibodies* produced in the laboratory from a single copy of a human *antibody* that can target specific cancer cells wherever they may be in the body.

**Monoclonal gammopathy of uncertain significance (MGUS)**
A condition in which increased numbers of abnormal *plasma cells* produce identical (monoclonal) *antibodies*. The condition is of little significance in itself and does not require treatment. However, 20-30% of people with MGUS go on to develop *myeloma*.

**Morphology**
The shape, size and general appearance of cells under a microscope.

**Multiple myeloma**
See *myeloma*.

**Myelodysplasia**
Abnormal formation of blood cells in the *bone marrow*.

**Myelodysplastic syndrome (MDS)**
A group of diseases in which the *bone marrow* functions abnormally and fails to produce enough normal blood cells. It may progress to *acute myeloid leukaemia*.

**Myeloid leukaemia**
A type of *leukaemia* in which the *white blood cells* produced in excess are those produced by myeloid *stem cells*. Also see *acute myeloid leukaemia* and *chronic myeloid leukaemia*.

**Myeloma/multiple myeloma**
A type of cancer characterised by the uncontrolled production of *plasma cells* in the *bone marrow* (myeloma cells). As it can develop in many places simultaneously, it is also known as multiple myeloma.
**Myeloproliferative disorders (MPD)**
Disorders in which too many blood cells are made by the bone marrow with increased numbers of red cells, white cells or platelets in the blood.

**Neoplastic disease**
Disease characterised by new and abnormal growth of tissue (cancer).

**Nephrology**
A branch of medicine concerned with the diagnosis and treatment of diseases of the kidneys.

**Neutropenia**
A condition in which the number of granulocytes (neutrophils) in the blood is below normal.

**Neutropenic sepsis**
Life-threatening infection made more severe by the reduced neutrophils.

**Neutrophils**
A specific sub-type of granulocyte.

**Non-Hodgkin's lymphoma (NHL)**
Any cancer of the lymphatic system other than Hodgkin's lymphoma. There are two main groups - high grade which are aggressive and fast growing and low grade which are slow growing (also known as indolent lymphomas). High grade lymphomas include: diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma, Burkitt's lymphoma, mantle cell lymphoma and AIDS-related lymphoma. Low grade or indolent lymphomas include: follicular lymphomas, Waldenstrom's lymphoma and marginal zone lymphomas. Extra-nodal lymphomas are those that develop outside lymph nodes such as those affecting the skin or intestine.

**Oncologist**
A doctor who specialises in treating cancer.

**Oncology**
The study of the biology and physical and chemical features of cancers. Also the study of the causes and treatment of cancers.

**Palliative**
Anything which serves to alleviate symptoms due to the underlying cancer but is not expected to cure it. Hence palliative care.

**Paraprotein**
An abnormal antibody produced by myeloma cells.
Pathologist
A person who specialises in the diagnosis of disease through study of the microscopic structure of cells and tissues.

Peripheral blood stem cells
_Storm cells_ in the bloodstream (as opposed to the _bone marrow_).

Philadelphia chromosome
A chromosomal abnormality found in the blood cells of all people with _chronic myeloid leukaemia_.

Plasma cells
Plasma cells are a type of _lymphoid cell_. They produce _antibodies_ (also called immunoglobulins) in response to infection.

Positron emission tomography (PET)
A highly specialised imaging technique used to produce a computerised image of metabolic activity of body tissues.

Precursor
A substance from which another substance is formed.

Progenitor cells
Parent cells that give rise to progeny that serve more specialised functions e.g. _stem cells_.

Prophylaxis
An intervention used to prevent an unwanted outcome.

Protocol
A policy or strategy which defines appropriate action.

Psychosocial
Concerned with psychological influence on social behaviour.

Pulmonary
Having to do with the lungs.

Quality of life
The individual's overall appraisal of his/her situation and subjective sense of well-being.

Radioimmunotherapy
Treatment with a radioactive substance linked to _antibodies_ in order to specifically target tumour cells.
**Radiologist**
A doctor who specialises in creating and interpreting pictures of areas inside the body. An interventional radiologist specialises in the use of imaging techniques to assist treatment e.g. the insertion of intravenous catheters.

**Radiotherapy**
The use of radiation, usually x-rays or gamma rays, to kill cancer cells.

**Randomised controlled trial (RCT)**
A type of experiment which is used to compare the effectiveness of different treatments. The crucial feature of this form of trial is that patients are assigned at random to groups which receive the interventions being assessed or control treatments. RCTs offer the most reliable (i.e. least biased) form of evidence of effectiveness.

**Recurrence**
The return of cancer.

**Remission**
A period when cancer has responded to treatment and there are no signs of cancer or cancer-related symptoms.

**Renal**
Having to do with the kidneys.

**Serum**
The clear liquid that separates from blood on clotting.

**Spleen**
An organ which is part of the lymphatic system. It produces lymphocytes, stores blood cells, filters the blood and removes and destroys worn-out red blood cells.

**Squamous cell carcinoma**
Cancer originating in squamous cells - thin, flat cells resembling fish scales - found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the respiratory and digestive tracts.

**Staging**
The extent (stage) of disease defined by internationally agreed criteria. Staging helps determine treatment and indicates prognosis.
**Stem cell harvesting**
Collection of stem cells either from the bone marrow (for bone marrow transplantation) or the bloodstream (for stem cell transplantation). Stem cells are normally found in the bone marrow. However, the bone marrow can be stimulated to produce lots of stem cells by the administration of growth factors (see colony-stimulating factors) causing the stem cells to spill into the bloodstream for easier collection. If the stem cells are being collected for autologous transplantation, they may be purged to destroy any remaining malignant cells before being preserved until required.

**Stem cell rescue**
See stem cell transplantation.

**Stem cells**
Blood cells at their very earliest stage of development; they may become red cells, white cells or platelets.

**Stem cell transplantation**
A procedure similar to a bone marrow transplant, but using stem cells obtained from the blood rather than from the bone marrow.

**Steroids**
Steroids are hormonal substances naturally produced in the body. They can also be made artificially and used as drugs. Some types of steroid have been found to destroy some types of cancer cells and can make chemotherapy more effective.

**Thrombosis**
Formation or presence of a blood clot within a blood vessel.

**Total body irradiation (TBI)**
Radiation to the whole body.

**Ultrasound**
High-frequency sound waves used to create images of structures and organs within the body.

**Vascular**
Having to do with blood vessels.

**White blood cells**
Blood cells that do not contain haemoglobin. They are part of the immune system and are present in the blood and lymphatic system, including the lymph glands and spleen. The bone marrow produces a number of different types of white blood cells which work together to fight infection.
## Appendix 5

### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABVD</td>
<td>Adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine</td>
</tr>
<tr>
<td>AIDS</td>
<td>Acquired immune deficiency syndrome</td>
</tr>
<tr>
<td>ALL</td>
<td>Acute lymphoblastic leukaemia</td>
</tr>
<tr>
<td>AML</td>
<td>Acute myeloid leukaemia</td>
</tr>
<tr>
<td>BCSH</td>
<td>British Committee for Standardisation in Haematology</td>
</tr>
<tr>
<td>BEAM</td>
<td>Carmustine (BCNU), etoposide, cytosine arabinoside and melphalan</td>
</tr>
<tr>
<td>BMT</td>
<td>Bone marrow transplantation</td>
</tr>
<tr>
<td>BSBMT</td>
<td>British Society for Bone Marrow Transplantation</td>
</tr>
<tr>
<td>BUCY</td>
<td>Busulphan-cyclophosphamide (conditioning for BMT)</td>
</tr>
<tr>
<td>CCT</td>
<td>Controlled (non-randomised) trials</td>
</tr>
<tr>
<td>CHI</td>
<td>Commission for Health Improvement</td>
</tr>
<tr>
<td>CHOP</td>
<td>Cyclophosphamide, doxorubicin, vincristine and prednisolone</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>CLL</td>
<td>Chronic lymphocytic leukaemia</td>
</tr>
<tr>
<td>CML</td>
<td>Chronic myeloid leukaemia</td>
</tr>
<tr>
<td>CMV</td>
<td>Cytomegalovirus</td>
</tr>
<tr>
<td>CNS</td>
<td>Clinical Nurse Specialist</td>
</tr>
<tr>
<td>CODOX-M</td>
<td>Cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate</td>
</tr>
<tr>
<td>CPA</td>
<td>Clinical Pathology Accreditation (UK) Ltd</td>
</tr>
<tr>
<td>CSF</td>
<td>Colony-stimulating factors</td>
</tr>
<tr>
<td>CT</td>
<td>Computed tomography</td>
</tr>
<tr>
<td>C-VAMP</td>
<td>Cyclophosphamide, vincristine, adriamycin (doxorubicin) and methyl prednisolone</td>
</tr>
<tr>
<td>DLBCL</td>
<td>Diffuse large B-cell lymphoma</td>
</tr>
<tr>
<td>EBMT</td>
<td>European Group for Blood and Marrow Transplantation</td>
</tr>
<tr>
<td>ENT</td>
<td>Ear, nose and throat</td>
</tr>
<tr>
<td>EQA</td>
<td>External quality assurance</td>
</tr>
<tr>
<td>ESHAP</td>
<td>Etoposide, methyl prednisolone, cytarabine and cisplatin</td>
</tr>
<tr>
<td>ESR</td>
<td>Erythrocyte sedimentation rate</td>
</tr>
<tr>
<td>G-CSF</td>
<td>Granulocyte-colony-stimulating factor</td>
</tr>
<tr>
<td>HEPA</td>
<td>High efficiency particulate air</td>
</tr>
<tr>
<td>HICPAC</td>
<td>Healthcare Infection Control Practices Advisory Committee</td>
</tr>
<tr>
<td>Acronym</td>
<td>Full Form</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HLA</td>
<td>Human leukocyte antigens</td>
</tr>
<tr>
<td>ICE</td>
<td>Ifosfamide, carboplatin and etoposide</td>
</tr>
<tr>
<td>JACIE</td>
<td>Joint Accreditation Committee EBMT-EurolSHAGE</td>
</tr>
<tr>
<td>JCCO</td>
<td>Joint Council for Clinical Oncology</td>
</tr>
<tr>
<td>MDS</td>
<td>Myelodysplastic syndrome</td>
</tr>
<tr>
<td>MDT</td>
<td>Multi-disciplinary team</td>
</tr>
<tr>
<td>MGUS</td>
<td>Monoclonal gammopathy of uncertain significance</td>
</tr>
<tr>
<td>MOPP</td>
<td>Mechlorethamine, vincristine, procarbazine and prednisone</td>
</tr>
<tr>
<td>MPD</td>
<td>Myeloproliferative disorders</td>
</tr>
<tr>
<td>MRC</td>
<td>Medical Research Council</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>NCA</td>
<td>National Cancer Alliance</td>
</tr>
<tr>
<td>NCRN</td>
<td>National Cancer Research Network</td>
</tr>
<tr>
<td>NHL</td>
<td>Non-Hodgkin’s lymphoma</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Clinical Excellence</td>
</tr>
<tr>
<td>ONS</td>
<td>Office for National Statistics</td>
</tr>
<tr>
<td>OR</td>
<td>Odds ratio</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PET</td>
<td>Positron emission tomography</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>REAL</td>
<td>Revised European-American Classification of Lymphomas</td>
</tr>
<tr>
<td>SBU</td>
<td>Swedish Council on Technology Assessment in Health Care</td>
</tr>
<tr>
<td>SRD</td>
<td>State registered dietitian</td>
</tr>
<tr>
<td>TBI</td>
<td>Total body irradiation</td>
</tr>
<tr>
<td>UKALL</td>
<td>United Kingdom Acute Lymphoblastic Leukaemia trials</td>
</tr>
<tr>
<td>UKMF</td>
<td>United Kingdom Myeloma Forum</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organisation</td>
</tr>
</tbody>
</table>